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DISCLAIMER 
 
 
The guidelines in this report represent a consensus of opinions of the members of the Iowa Antibiotic 
Resistance Task Force (IARTF).  They do not constitute official policy.  This report was created to 
provide a concise practical guide for all public health workers and health care providers regarding the 
evolving problem of antibiotic resistance as it relates to patients, residents and clients in Iowa.   
 
The report is organized by type of setting to enable the user to read specific sections of interest 
without having to read the entire report.  All readers are urged to become familiar with the 
introduction, bibliography and additional sections that pertain to their particular setting.  The IARTF 
hopes you will find this publication useful. 
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OVERVIEW 
 
 
On January 29, 1998, a task force was convened by the Iowa Department of Public Health (IDPH) to 
address the development of bacterial resistance to antibiotics in Iowa. The purpose of this task force 
was to evaluate and monitor the prevalence of resistance in Iowa, to monitor the status of the 
problem, and to develop strategies to diminish the risk to the population of Iowa.  The goals of the 
Iowa Antibiotic Resistance Task Force (IARTF) are to facilitate appropriate use of antibiotics, 
discourage prescribing practices that promote the development of antibiotic resistance, and decrease 
the spread of antibiotic-resistant organisms with appropriate prevention and control measures.  This 
group has been meeting since 1998 to accomplish these goals.  Current members of the IARTF 
represent a number of concerned organizations: 
 
Iowa Academy of Family Physicians 
Iowa Chapter, American Academy of Pediatrics 
Iowa Dental Association 
Iowa Department of Public Health 
Iowa Health Care Association 
Iowa Hospital Association 
Iowa Medical Society 
Iowa Nurses Association 
Iowa Pharmacy Association 
Iowa Veterinary Medical Association 
Iowa‘s Statewide Epidemiology Education and Consultation Program 
State Hygienic Laboratory 
University of Iowa Hospitals and Clinics 
 
Nationwide, the medical and public health community has become aware of the increase in the 
numbers of microbial species which have developed resistance to antibiotics as well as their growing 
endemicity or prevalence.  Eleven isolates of vancomycin-resistant Staphylococcus aureus (VRSA) 
have been reported to date in the United States.  However, population-based data to assess 
antibiotic resistance have been limited.  With emerging antibiotic resistance possibly related to 
geographical and demographic variables, state and local data becomes invaluable.  Upon the 
recommendation of the IARTF, a comprehensive statewide, laboratory-based surveillance program 
began on January 1, 1999.  This program, through IDPH and the State Hygienic Laboratory (SHL), 
was designed to detect and monitor antibiotic resistance throughout the state of Iowa.  
 
The surveillance included invasive disease caused by these organisms:  
 
Enterococcus species,  
 
Group A Streptococcus (GAS),  
 
Methicillin-resistant Staphylococcus aureus (MRSA),  
 
Streptococcus pneumoniae.  
 
Additionally, Staphylococcus aureus resistant to vancomycin (VRSA) from any site was included in 
the program. 
 
This statewide surveillance program ended January 1, 2011 due to lack of funding. 
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However VRSA remains reportable under IAC 641.1.  Information should be called immediately to 
IDPH at 800 362-2736 and the isolate sent to SHL 
 
The IARTF encourages all readers to review the updated information and guidelines provided.  In 
addition, there are many professional organizations that offer excellent resources for patient 
educational material, information on the impact of antibiotic resistance and recommendations in 
specific settings regarding this issue. IARTF representatives have reviewed the literature and have 
provided an extensive bibliography that may be very helpful to public health workers and health care 
providers during this educational process. 
 
The IARTF‘s multidisciplinary approach signifies its joint interest in the evolution of antibiotic 
resistance.  The IARTF urges all readers and especially public health workers and health care 
providers to educate themselves on this complicated and changing subject. 
 
―Good antimicrobial stewardship entails more than consideration of the 
immediate benefit to the individual patient being treated.  It also considers 
the long-term effects of use on the future preservation of susceptibility in 
the practice population of the prescriber.‖ 
  
McGowan, J.E. Jr. and Gerding, D.N. 
New Horizons 1996: 4:370-376. 
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ANTIBIOTIC USE 
 
 
Methods to prevent the development of antibiotic resistance must include appropriate and judicious 
use of antibiotics.  Numerous studies establish a relationship between the use of antibiotics and 
development of resistance by microorganisms.  In general, the greater the exposure to antibiotics, 
the more resistance develops.  The likely and undesirable outcome is an increased population of 
resistant organisms causing increasingly untreatable infections.  New measures focused on changing 
the patterns of use of antibiotics are necessary to slow the rise of resistance.   
 
Ensuring appropriate use of antibiotics will take a concerted and coordinated effort of patients, public 
health, medical institutions and health care providers.  This multidisciplinary approach, where all 
parties have ownership in the issue and strive for the same outcomes, will be most successful.  
Achieving appropriate use of antibiotics will thus require behavioral changes not only in the medical 
community but the public as well. 
 
Strategies to accomplish judicious use of antibiotics include development of guidelines or pathways 
of prescribing for optimal use.  Health care providers should be encouraged to follow guidelines and 
obtain expert guidance from infectious disease specialists when appropriate.  Antibiotics can also be 
removed from the clinical formularies or controlled based on surveillance data for a geographic area 
or institution.  Rotational use of antibiotics and use of combination therapy are other methods that 
can be effective at reducing resistance.  Contemporary medical practice is refocusing on the judicial 
use of antibiotics through formalized ―stewardship‖ programs as well as reinforcing traditional 
infection prevention and control strategies.         
 
In the outpatient clinic setting, the strategies for appropriate use may be more directed.  Antibiotics 
are commonly prescribed for upper respiratory infections most of which are caused by viruses.  
Reserving antibiotics for clinically diagnosed bacterial complications of the URI (e.g. otitis media, 
sinusitis) would be a more appropriate approach to antibiotic use.  For most URIs, antibiotics should 
not be the accepted or expected treatment and patient education about symptomatic care and the 
expected course of illness should be the norm.   
 
When antibiotics are indicated, practitioners should strive to have all patients treated with the most 
effective, least toxic, and least costly regimen for the duration necessary to cure or prevent infection.  
Whether the patient is prescribed an antibiotic or not, there are several messages that all members 
of the medical team must emphasize to help achieve appropriate use.  Taking the time to deliver 
these messages is the key to educating the consumer.   
 
The following guidelines address some measures to achieve the appropriate use of antibiotics: 
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Guidelines for Antibiotic Use 
 
 
 Obtain appropriate cultures and interpret results with care.  Restrict antibiotics to patients with 
bacterial infections.  Patients must be educated that antibiotics are not appropriate for viral 
infections. 
 
 Choose the narrowest-spectrum, most targeted antibiotic possible. 
 
 Follow established institutional guidelines or prescribing pathways to ensure appropriate 
selection.  
 
 Reserve long-term and perioperative antibiotic prophylaxis for specific clinical conditions where 
the benefit - risk ratio has been well established. 
 
 Refrain from using antibiotics as an antipyretic.  Empiric use of broad-spectrum antibiotics for 
fever will only increase the chance for resistance to develop, and put patients at risk for an 
adverse reaction. 
 
 Take time to educate patients when they request antibiotics for viral illnesses.  Tell patients that 
antibiotics will not help the condition and have potential harmful effects.  Explain the natural 
course expected in this condition and what symptomatic care is appropriate.  Educate patients 
about the symptoms of bacterial complications and to when to seek re-evaluation. 
 
 Take measures to ensure that patients use antibiotics properly when their use is appropriate.  
Antibiotics must be taken exactly as prescribed - at correct intervals and for the indicated length of 
time.  Patients should also be instructed not to save antibiotics for future illnesses, not to take 
―leftover‖ antibiotics, and not to share antibiotic prescriptions with others.  
 
These general guidelines should apply to all health care providers.  More specific guidelines 
regarding antibiotic prescribing may be found in the section referred to as Primary Care.  
All providers who work in the primary care setting are urged to read this additional section. 
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LABORATORY 
 
 
 
 
Testing Considerations for Laboratories 
     
 
 Laboratories must adhere to the current Clinical and Laboratory Standards Institute (CLSI) 
guidelines to determine when susceptibility testing should be done on an organism, the method 
preferred, and appropriate drugs of choice for testing.   
 
 When a facility‘s cost or personnel considerations render appropriate susceptibility testing 
impossible, these organisms should be referred to a facility certified by the Clinical Laboratory 
Improvement Act (CLIA), which adheres to CLSI guidelines and provides data within a turn-
around time consistent with optimum patient care. 
 
Over the past few years new information and changes in the guidelines for susceptibility testing have 
been developed.  These testing modifications are described in detail in the latest CLSI guidelines.   
 
 VISA and VRSA 
To date there have been eleven isolates of vancomycin-resistant Staphylococcus aureus (VRSA) 
identified in the United States, none in Iowa.   A few existing factors seem to predispose case 
patients to VRSA infection, including:  
Prior MRSA and enterococcal infections or colonization, 
Underlying conditions such as chronic skin ulcers and diabetes, and   
Previous treatment with vancomycin  
 
Detection of a Staphylococcus aureus isolate with reduced susceptibility to vancomycin is a 
critical part of monitoring susceptibility patterns in your laboratory. 
 
Current CLSI standard breakpoints for vancomycin when tested against Staphylococcus 
aureus are as follows: 
1
 
Susceptible    ≤ 2 µg/mL 
Intermediate      4-8 µg/mL 
Resistant     ≥ 16 µg/mL 
 
Staphyloccocus aureus isolates should be tested by a reference MIC method. The disk 
diffusion procedure will not differentiate strains with reduced susceptibility to vancomycin 
(MICs 4 to 8 μg/mL) from susceptible strains (MIC range 0.5 to 2 μg/mL) even when incubated 
for 24 hours. Additionally, vancomycin resistant S. aureus (VRSA) strains (MICs =16 μg/mL) 
may produce only subtle growth around a vancomycin disk (CLSI M100). 
 
A brain heart infusion (BHI) vancomycin agar screen plate containing 6 μg/mL of vancomycin, 
such as that used for detection of vancomycin-resistant enterococci (see M7, Table 2D), may 
be inoculated to enhance the sensitivity of detecting vancomycin-intermediate and 
vancomycin-resistant strains of S. aureus. (CLSI M100) 
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Any laboratory that finds a Staphylococcus aureus isolate (regardless of source) with a 
vancomycin breakpoint of ≥2 µg/mL should contact SHL or refer to the Sentinel Lab Page on 
their website (www.shl.uiowa.edu) for instructions on sending the isolate to the SHL. 
 
SHL will evaluate the MIC by reference methods to determine if the isolate has reduced 
susceptibility.   
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Numbers of Invasive Isolates Submitted to SHL during the  
Iowa Antibiotic Resistance Surveillance Program 
 
 
 
 
 
 
Submissions of invasive  Group A Streptococcus isolates flucutated every 2-3 years until 2008 and 2009  
when we saw a large increase to 90+ submissions for each year. Since overall submission of all organisms  
o the surveillance project increased during these years, we cannot determine the significance of this  
increase. 
 
 
 
 
 
Data for submission of invasive isolates of Enterococcus species includes isolates of Enterococcus faecium 
and Enterococcus faecalis. While there was a slight decline in these submissions for about 3 years after the 
first year of the program, we have seen an increase in these isolate submissions each year since 2003.  
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Submission of invasive isolates of MRSA has steadily increased since the start of the surveillance program in 
1999. Submissions have remained stabile for the last few years with close to 450 isolate submissions for each 
of years 2007, 2008 and 2009. Since evaluation of the surveillance program several years ago indicates that 
only about 45% of isolates qualifying for submission were actually being submitted by clinical labs, there is 
reason to believe that the incidence of invasive MRSA is actually higher than shown here. 
 
 
 
 
Invasive Streptococcus pneumoniae isolate submissions has been fairly steady since the year 2000. Iowa did 
see a drop in the number of invasive isolates from children less than five years of age with the advent of the 
pneumococcal vaccines. 
 
  
11 
 
Instructions for submitting Vancomycin resisitant – or 
Vancomycin intermediate – Staphylococcus auereus to 
State Hygienic Laboratory (SHL) 
Is the organism 
Vancomycin –resistant 
or –intermediate 
Staphylococcus aureus 
from any source 
Call IDPH 800-362-2736; 
institute infection control 
precautions;  
call SHL 319-335-4335; 
ship isolate to SHL by 
courier or overnight carrier 
Do Not Send 
No 
Yes 
Yes 
Call SHL immediately for submission instructions.  We will 
want the isolate that has undergone the least amount of 
subculture. (ex: the isolate from the purity plate you set up 
when doing an automated susceptibility) 
Has the same species or strain from the 
same patient (same or different body 
site) been submitted in the last 30 days? 
Do Not Send 
Yes 
Means of transport will be decided during your consultation call to SHL.  Be sure to 
include the properly completed SHL Bacteriology test request form.  For test, select 
―Miscellaneous culture‖ and write in confirmation of VISA/VRSA on the ―Specify‖ 
line. Go www.shl.uiowa.edu/kitsquotesforms/bacteriologyrequestform.pdf 
to print the form 
No 
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PREVENTION AND CONTROL MEASURES 
for Persons with Multidrug Resistant Organisms or 
Clostridium difficile IN SPECIFIC SETTINGS 
 
 
A variety of health care facilities, including hospitals and long-term care, have experienced an 
increase in multidrug- resistant organisms (MDRO) including methicillin-resistant Staphylococcus 
aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) or Clostridium difficile.  Antibiotic 
resistant organisms can develop in patients who receive broad-spectrum antibiotics and in those who 
receive care in various health care settings.   
 
A multidisciplinary approach including physicians, veterinarians, public health workers, pharmacists, 
nurses and personnel from infection prevention and performance improvement programs, pharmacy 
and therapeutics committees, microbiology laboratories, and health care facilities is needed to control 
these organisms.  All involved should develop strategies to detect, prevent, and control colonization 
and infection of patients with multidrug resistant organisms. 
 
The following sections contain guidelines and strategies for reducing the risk of antibiotic resistance 
in various settings including:  primary care, acute care, long-term care, psychiatric inpatient care, 
partial hospitalization and day treatment programs, dental offices, home care and hospice, 
hemodialysis units, schools and child care, veterinary practices, the community, and correctional 
facilities.  The summaries of specific measures were developed by the Iowa Antibiotic Resistance 
Task Force (IARTF) members and are based on articles cited in the bibliography.  Providers are 
encouraged to educate themselves regarding strategies to combat antibiotic resistance in their 
specific area of practice. 
 
 
Hand Hygiene 
 
 
 
Definitions: 
 Alcohol-based hand rub:  an alcohol-containing preparation designed to reduce the number of 
viable microorganisms on the hands.  Such preparations contain 60 – 90 percent ethanol or 
isopropanol.   
 Antimicrobial soap:  soap (i.e., detergent) containing an antiseptic agent. 
 Antiseptic agent:  antimicrobial substances (e.g., alcohols) that are applied to the skin to reduce 
the number of microorganisms.   
 Hand hygiene:  general term that applies to either hand washing with plain liquid soap,   or hand 
antisepsis by washing with an antiseptic soap or by using an alcohol-based hand rub. 
 Hand washing:  washing hands with plain, (i.e., non-antimicrobial) soap and water. 
 Hand antisepsis:  refers to either washing hands with an antimicrobial soap or to rubbing an 
alcohol-based waterless product on the hands until they are dry.   
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General Information: 
 Hand hygiene is the single most important procedure for preventing the spread of microorganisms 
that cause infections. 
 Microorganisms that are carried on the skin for short periods of time (i.e., transient flora) can be 
transmitted to susceptible patients who could subsequently acquire health care-associated 
infections. 
 
Health Care Workers: 
 Health care workers should wash their hands to remove:  
Visible contamination or soil, 
Transient microorganisms acquired by recent contact with infected or colonized patients or 
contaminated environmental sources. 
 Health care workers should perform hand antisepsis to:  
Eliminate transient microorganisms,  
Reduce resident or colonizing microorganisms. 
 
 Perform hand washing: 
When hands are visibly dirty or contaminated with blood or body fluids, 
 
After contact with body fluids or excretions, mucous membranes, non-intact skin, or wound 
dressings, 
 
When caring for patients with diarrhea, 
 
Before eating, preparing or serving food, 
 
After using the bathroom. 
 
Caring for patients with Bacillus anthracis,Clostridium difficile (spore formers) or norovirus,  
 Washing hands with non-antimicrobial or antimicrobial soap and water may help to 
physically remove spores from the surface of contaminated hands. 
 If your institution experiences an outbreak, consider using only soap and water for 
hand hygiene when caring for patients with Clostridium difficile or norovirus infection.  
 
 Perform hand antisepsis:  
Before donning sterile gloves when performing tasks such as inserting a central venous 
catheter, a urinary catheter, a peripheral vascular catheter, or other invasive devices that do 
not require a surgical procedure for insertion, 
 
When patients are colonized with MRSA, VRE or any MDRO, 
 
When hands are not visibly soiled. 
  
 Perform hand antisepsis or hand washing: 
Before having direct contact patients, 
 
After contact with patient‘s intact skin (e.g., taking a pulse or blood pressure or lifting a 
patient), 
 
If moving from a contaminated body site to a clean body site during patient care (e.g., after 
suctioning the endotracheal tube and before cleaning the exit-site of the central venous 
catheter), 
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After contact with inanimate objects (including equipment) in the immediate vicinity of the 
patient, 
 
After removing gloves, because hands may be contaminated during or after glove removal. 
 
Patients: 
 Patients should wash their hands: 
When hands are visibly contaminated or soiled,  
  
Before leaving room, 
 
Before eating, preparing or serving food, 
  
After toileting. 
 
 Patients should use alcohol-based hand rub: 
     If colonized with MRSA, VRE, or any MDRO. 
 
If patients are unable to wash their hands, health care workers should assist them with hand hygiene. 
 
Equipment Needed: 
Hand Hygiene 
 Hand washing  
Non-antimicrobial soap, 
Warm running water, 
Paper towels. 
 
             Or 
 
 Hand Antisepsis (preferred method) 
Alcohol-based waterless hand rub. 
 
  Or 
 
Hand Antisepsis  
Antimicrobial soap, 
Warm running water, 
Paper towels. 
       
Procedure: 
Hand washing or hand antisepsis with antimicrobial soap 
 Adjust running water to a comfortable temperature, 
 Adjust the force of the water to prevent contamination of surrounding area by splashing water, 
 Wet hands, 
 Use soap dispenser with foot, knee, or hand controls and dispense enough soap to achieve a rich 
lather (or as per manufacturer‘s recommendation.) 
 Using friction, lather soap on hands for at least 15 seconds, 
 Rub all surfaces of fingers, palms, back and sides of hands, 
 Pay particular attention to the medial areas of the fingers, fingertips and nail beds, 
 Rinse hands well, 
 Dry hands thoroughly with paper towels, 
 Turn off hand controlled faucets using paper towel to protect hands from recontamination, 
 Discard paper towels. 
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Hand Antisepsis with alcohol 
Be sure hands are not visibly soiled.  If visibly soiled, wash hands first.   
 Apply 3-5 ml of gel to hands.   
 Spread over all surfaces of fingers and hands, 
 Pay particular attention to the medial areas of the palms, backside of hands, fingers, fingertips, 
between fingers, and nail beds, 
 Rub the solution vigorously into hands until dry (approximately 15-30 seconds).   
 When hands begin to feel sticky (usually after several uses of an alcohol-based hand rub), wash 
them with plain soap and water. 
 
Skin Care: 
Hospital approved hand lotions or creams that are latex and chlorhexidine (CHG) compatible should 
be available for health care workers to use.   
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PRIMARY CARE 
 
 
The proliferation of bacteria resistant to multiple antibiotics has become an increasingly important 
health issue for individual patients and for communities.  There is little question that this has resulted 
in part from the widespread use of antibiotics and the selective pressure these agents apply to 
bacterial populations.  Antibiotic resistance can increase the cost of health care by prolonging 
hospitalizations and increasing the use of expensive antibiotic agents.  Infections with multidrug- 
resistant bacteria can also increase morbidity and mortality.  
 
The primary care provider must play a pivotal role in preventing and controlling the spread of 
resistant organisms.  Primary care providers have the responsibility to provide quality health care to 
their patients and at the same time must share responsibility for the health of the community.  With 
respect to antibiotic resistance, this dual task can best be accomplished when antibiotics are 
prescribed on a selective and thoughtful basis. 
 
 
Guidelines for Primary Care 
 
 
General principles 
 
 Patients should  
 Be educated not to expect antibiotics for viral illnesses,  
 Be informed about the potential dangers associated with unnecessary antibiotic use,   
 Be aware of the appropriate length of therapy and the importance of completing a full 
course of antibiotics, and   
 Be instructed not to save antibiotics for future illnesses, not to take ―leftover‖ antibiotics, 
and not to share their prescriptions with others. 
 Most common respiratory tract infections are viral: influenza, common cold, croup, laryngitis, 
most bronchitis and most pharyngitis.  Patients with these common infections should be 
educated on  
 The relief that symptomatic care can provide,  
 The natural course of the illness and  
 When to call back to the office. 
 Antibiotics should be reserved for patients that develop bacterial complications of these 
common viral ailments – including otitis media, sinusitis and pneumonia.   
 Diagnosis and management guidelines for several bacterial infections of the upper airway are 
presented below.  These recommendations are a compilation of several evidence-based, 
nationally accepted clinical practice guidelines. 
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Acute Otitis Media 
 
 Diagnosis requires a history of acute onset, evidence of middle ear effusion, and signs and 
symptoms of inflammation of the middle ear. Evidence of middle ear effusion includes: 
otoscopic changes such as bulging from neutral position, limited or absent mobility to 
pneumatic otoscopy, air fluid levels or otorrhea.  Signs or symptoms of inflammation would be 
indicated by opacity (pus) behind the tympanic membrane (TM), distinct erythema of the TM, 
and pain clearly referable to the ear(s). 
 Acute otitis media (AOM) should not be confused the otitis media with effusion (OME).  OME 
is the presence of middle ear effusion without signs or symptoms of an acute ear infection (no 
inflammation).  The primary treatment of OME does not include use of antibiotics, therefore 
this condition is not addressed here. 
 Selected children with uncomplicated AOM can be observed.  This approach involves 
deferring antibacterial treatment for 48-72 hours and limiting management to symptomatic 
relief.  This approach should be limited to otherwise healthy children two years of age and 
older without severe symptoms who are likely to return for follow up if necessary. 
 If the clinician decides to treat the patient with an antibiotic, amoxicillin (at 80-90 mg/kg/day in 
two divided doses) should be used for most children. 
 Children whose AOM did not respond to amoxicillin therapy may be infected with beta-
lactamase-producing H influenzae or Moraxella catarrhalis.  Amoxicillin clavulanate 14:1 (80-
90 mg/kg per day amoxicillin component in two divided doses) or a cephalosporin (oral 
cefdinir, cefuroxime, cefpodoxime, or parenteral ceftriaxone, 50 mg/kg once daily for three 
days, intramuscularly) could be considered as therapy for these patients. 
 Middle ear effusion without inflammation (OME) is often present at the end of therapy.  This 
can last two to three months and does not require any treatment. 
 
Sinusitis 
 
 Clinical diagnosis of acute bacterial sinusitis requires the presence of nasal discharge (of any 
quality) without improvement for 10-14 days or fever ≥102º F and purulent nasal discharge of 
at least 3 consecutive days in a person who appears ill.  Facial pain or tenderness and 
periorbital swelling and redness are more specific indicators of acute sinusitis in older children 
and adults. 
 Antibiotic therapy is only indicated after these strict criteria for diagnosis are met.  Antibiotic 
therapy is identical to that recommenced for otitis media (above). 
 The common cold is a rhino-sinusitis that often includes radiologic or computed tomography 
evidence of sinus involvement. Therefore, imaging studies should be used only in selected 
circumstances (i.e., suspicion of complications, recurrent disease) and should be interpreted 
with caution.   
 
Pharyngitis 
 
 Infectious causes of pharyngitis can be bacterial or viral (viral being much more common).  
Antibiotic therapy is indicated for group A Streptococcus (GABS) and for the very rare 
infections caused by certain bacterial pathogens such as Corynebacterium diphtheriae, 
Neisseria gonorrhoeae and group C and G Streptococci.  In general, antibiotic therapy has not 
been proven to benefit patients with acute pharyngitis caused by other bacterial species.  
 The signs and symptoms of GABS pharyngitis and viral pharyngitis overlap broadly.  
Therefore, a laboratory test should be done to determine whether GABS are present in the 
pharynx prior to determining appropriate therapy.  A rapid antigen detection test (RADT) 
should only be done if clinical and epidemiological features are suggestive of GABS 
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pharyngitis.  These features include sudden onset, sore throat, fever, pharyngeal 
inflammation, lymphadenopathy, patient age 5-15y, winter and spring season, and lack of cold 
symptoms (cough and runny nose).  A positive RADT is adequate to establish the diagnosis of 
GABS pharyngitis.  A negative RADT in children and adolescents should be confirmed by a 
throat culture.  Because of the low incidence of GABS in adults and the extremely low risk of 
rheumatic fever, a negative RADT does not need to be confirmed by culture in that population. 
 Antibiotic therapy is indicated for persons with symptomatic pharyngitis only after GABS has 
been confirmed by laboratory testing.  Several antibiotics have demonstrated efficacy against 
GABS including penicillins, cephalosporins and macrolides.  Tetracyclines and sulfonamides 
should not be used for treating GABS pharyngitis. 
 
The Common Cold (viral rhinosinusitis) 
 
 Antibiotics should not be given for the common cold. 
 Mucopurulent rhinitis (thick, opaque, or discolored nasal discharge) commonly accompanies 
the common cold and is not an indication for antibiotic treatment unless it persists without 
signs of improvement for 10 to 14 days, suggesting possible acute bacterial sinusitis. 
 Antibiotics do not effectively treat viral rhinosinusitis or prevent subsequent bacterial infections.  
Do not over diagnose sinusitis.  Although most colds involve the paranasal sinuses, only a 
small minority are complicated by bacterial sinusitis.  Avoid unnecessary treatment by using 
strict criteria as outlined for sinusitis. 
 
Acute Bronchitis (nonspecific cough illness)  
 
 Nonspecific cough illness (bronchitis), regardless of duration, in children or adults without 
underlying chronic pulmonary or heart disease, does not warrant antibiotic treatment. 
 Prolonged cough (>10-14 days) may be caused by Bordetella pertussis, Bordetella 
parapertussis, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.  When infection 
caused by these organisms is suspected clinically or confirmed, appropriate antibiotic therapy 
is indicated. 
 The evaluation of patients with an acute cough illness or presumptive diagnosis of 
uncomplicated acute bronchitis should focus on ruling out serious illness, particularly 
pneumonia. 
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HOSPITALS (ACUTE CARE FACILITY) 
 
 
The presence of multidrug- resistant organisms (MDROs) is becoming an increasingly difficult 
problem in hospitals.  As more resistant organisms emerge, therapeutic options available to the 
practitioner become more limited.   
 
Factors that contribute to the acquisition, and transmission, of multidrug-resistant organisms in acute 
care facilities include: 
 Previous use of antibiotic agents - especially those effective against a broad range of bacteria, 
 Use of invasive devices (e.g., urinary or intravascular catheters), 
 Sub-optimal recognition and reporting of antibiotic-resistant organisms by the clinical laboratory, 
 Unrecognized ―silent‖ carriage, 
 Environmental contamination and survival of the organism(s) on inanimate surfaces, 
 Intrahospital and interhospital transfer of colonized or infected patients, 
 Admission of patients who are unrecognized carriers from other health care facilities and from the 
community,  
 Inadequate compliance with hand hygiene and standard barrier precautions. 
  
A multidisciplinary approach is necessary to interrupt the transmission of multidrug- resistant 
organisms in the acute care setting.  Hospitals should develop an Infection Prevention and Control 
Plan that addresses prevention and control measures for this very complex problem.  The Iowa 
Antibiotic Resistance Task Force offers the following guidelines as strategies to decrease the risk of 
colonization with and transmission of multidrug-resistant organisms in the acute care setting. 
 
 
ACUTE CARE FACILITY 
Guidelines in Hospitals for patients with  
Multidrug-resistant organisms or Clostridium difficile 
 
 
 
 Room Assignment 
A private room is recommended.  The room should have a bathroom that is not shared, hand 
washing facilities in addition to those in the bathroom, and a dispenser of an alcohol-based 
hand hygiene product. 
 
When a private room is not available or when cohorting patients is not possible, place an 
infected or colonized patient who can cooperate with strategies to contain their bodily 
secretions with another patient who does not have underlying immunocompromising illness, 
open wounds, indwelling devices, or diarrhea.  
 
 Hand Hygiene 
Hand hygiene is the single most effective infection prevention and control measure for 
reducing transmission of all organisms, including those that are resistant to antibiotic agents. 
 
 
20 
 
All staff that provide direct patient care to patients with multidrug-resistant organisms should: 
Perform hand hygiene before and after every episode of care; use an alcohol-based 
product if hands are not visibly soiled or wash hands for at least 15 seconds if they are 
visibly soiled. Consider hand washing when caring for patients with Clostridium difficile 
or norovirus. 
 
Change gloves and perform hand hygiene when moving from a dirty site to a clean site 
on the same patient, 
 
Perform hand hygiene after removing gloves.      
 
Patients should: 
Wash their hands after toileting, 
 
Wash their hands or use an alcohol-based hand hygiene product before leaving the 
room for common areas or interacting with other persons, 
 
If patients are unable to wash their hands, health care workers should assist them with 
hand hygiene. 
 
 Isolation Precautions 
For Isolation Precautions refer to Centers for Disease Control and Prevention (CDC) 
Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in 
Healthcare Settings, 2007 and Management of Multidrug- Resistant Organisms in Healthcare 
Settings, 2006.  In addition to Standard Precautions, health care workers should observe 
Contact Precautions. 
 
Health care workers should: 
 
Wear a gown and gloves upon room entry when contact with the patient or patient‘s 
environment is anticipated or when contact is found to be necessary, 
 
Change gloves and perform hand hygiene between procedures on the same patient if 
the gloves become contaminated or when the health care worker moves from caring for 
a dirty to a clean site, 
 
Remove gloves and gowns and perform hand hygiene before leaving the patient's 
room, 
 
Use appropriate barriers on the patient when transporting patients outside their rooms 
for diagnostic testing, therapy, etc. 
 
 Criteria for Discontinuing Isolation Precautions for Patients in Acute Care Facilities 
The current Hospital Infection Control Practices Advisory Committee (HICPAC) guidelines for 
isolation precautions and for MDROs both indicate that  
 patients may remain colonized with these organisms at one or more body sites,  
 patients may shed these organisms intermittently,  
 surveillance cultures may fail to detect their presence, and  
 patients who appear to be decolonized can subsequently have positive cultures.  
 
CDC recommends that if a health care facility uses active surveillance cultures (ASC) to detect 
and isolate patients colonized with MRSA or VRE and the facility does not decolonize these  
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patients (note there are no good protocols for decolonizing patients with VRE), it is logical to 
use Contact Precautions for the duration of stay in the setting where they were first 
implemented. CDC also notes that it is reasonable to discontinue Contact Precautions when 
three or more surveillance cultures for the target MDRO are repeatedly negative over the 
course of a week or two in a patient who has not received antibiotic therapy for several weeks, 
especially in the absence of a draining wound, profuse respiratory secretions, or evidence 
implicating the specific patient in ongoing transmission of the MDRO within the facility. 
 
Acute care facilities should adopt criteria for determining when a patient with a multidrug-
resistant organism may be released from Contact Precautions.  The following suggestions are 
based on current expert opinion and limited available scientific data. 
 
MRSA - A patient with MRSA may have Contact Precautions discontinued after two cultures 
taken 24 - 48 hours apart are found to be negative for MRSA.  These cultures should be taken 
from each previously infected or colonized site and from the anterior nares.  (Some institutions 
also include the axilla, perineum and any open wounds in their basic protocol.)  Cultures of 
most sites should be taken at least 48 - 72 hours after antibiotics have been discontinued.  
Cultures of the nares should be obtained at least 48 hours after stopping nasal mupirocin.  
However, nares cultures can be obtained while the patient is on systemic antibiotic agents 
because most of these agents do not penetrate into the nasal secretions.   
     
VRE - A patient with VRE may have Contact Precautions discontinued after three consecutive 
cultures obtained at least one week apart are negative for VRE.  These cultures should be 
taken from multiple body sites (including stool, rectum, or perirectal area, any initial sites(s) of 
infection or colonization with VRE, and if present, open wounds, colostomy sites and catheter 
[urine]).  If the patient is on antibiotics, the antibiotics do not need to be discontinued before 
obtaining these cultures. 
 
Multidrug-Resistant Gram-negative Organisms (MDR-GNB) - CDC notes that there are few 
data in the literature indicating when it is safe to discontinue Contact Precautions for patients 
colonized with a MDR-GNB, possibly because infection and colonization with these MDROs 
are often associated with outbreaks. CDC recommends that Contact Precautions be used 
indefinitely in the context of an outbreak for all patients that were previously infected or known 
to be colonized with MDR-GNB. CDC has not addressed non-outbreak settings. 
 
Clostridium difficile – Patients who no longer have diarrhea may have Contact Precautions 
discontinued. Do not test asymptomatic patients to determine whether their tests for C. difficile 
are negative. 
 
 Mechanism to Flag the Records of Patients with MDRO When Introduced or Reintroduced 
Into the Health Care System 
Use a computer or other system to inform staff members about the patient‘s history of 
colonization or infection with resistant organisms at the time of admission, readmission and 
reintroduction into the health care system. This is not necessary for patients with a history of 
Clostridium difficile. 
 
 Criteria to Remove the MDRO Flag from Records of Patients 
Currently there is no set standard of removing the flag from a medical record.  Each facility 
should determine a process that works within their system and their patient population.   Below 
are two methods currently used in Iowa hospitals to determine removal of the flag from a 
patient‘s record: 
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MRSA and VRE: 
Hospital A: If a patient returns to a health care facility who has met criteria for discontinuing 
Contact Precautions, the flag should have already been removed during that prior stay. The 
protocol may be followed and criteria met as an outpatient The patient will not be isolated 
unless they have MRSA or VRE isolated from a new culture.   Patients who have not met 
criteria for discontinuing Contact Precautions or had Contact Precautions continued 
throughout their prior stay and their colonization status is unknown (no intervening cultures), 
then the patient is placed on Contact Precautions upon readmission and screening cultures 
are obtained (nares and open wound if present for MRSA, perirectal for VRE).   
 
Method B: The flag is left on the record for one year after the patient has met the criteria for 
discontinuing Contact Precautions during a particular visit.  During that year, if a patient has a 
negative culture documented within the past 30 days, the patient may be readmitted or seen 
without using Contact Precautions.  If there is not a documented negative culture in the past 
30 days, the patient must be readmitted or seen using Contact Precautions and surveillance 
cultures obtained.  If the cultures are negative, Contact Precautions may be discontinued. The 
flag is removed from the record after one year of negative cultures 
 
 Multidrug-Resistant Gram-negative Organisms (MDR-GNB): 
Method A: The record is not flagged for subsequent admissions. 
 
Method B: Flag is never removed from the record, but the patient may come out of Contact 
Precautions if not actively infected. 
 
         Clostridium difficile: 
Patients may be removed from Contact Precautions when they are no longer having diarrhea.  
A negative test is not necessary.  The patient‘s record is not flagged for subsequent 
admissions. 
 
 Equipment and Environment 
A disinfectant registered by the Environmental Protection Agency (EPA) should be used on 
surfaces such as furniture, door handles, and floors, in areas where patients have multidrug-
resistant organisms. 
 
If possible, dedicate reusable items to a specific patient in isolation for their use only.  Always 
clean and disinfect items after they are no longer needed to care for that patient.  If equipment 
must be shared, clean and disinfect the items between uses for different patients (e.g., 
stethoscope, sphygmomanometer, and electronic thermometer).  Do not use rectal 
thermometers for patients with VRE or Clostridium difficile. 
 
Limit use of commodes to patients who cannot get to the bathroom.  Commodes should not be 
shared. Commodes should be cleaned and disinfected when visibly soiled and periodically as 
with a toile.  If sharing does occur, clean and disinfect between patients. 
 
Clean and disinfect rooms daily and between patients. 
 
Educate staff about which disinfectant to use and how to dilute the product. 
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Instruct staff to remove all organic material before applying disinfectant and leave the 
disinfectant on the surfaces for the appropriate amount of time (contact time), following the 
manufacturer‘s directions. 
 
Limit items entering the patient‘s room. 
 
No special precautions are needed for handling food or soiled dishes. 
 
Follow routine practices for handling trash: place non-hazardous trash in ordinary waste 
receptacles; place all regulated trash in red containers or containers with a biohazard label. 
 
 Transferring Patients 
The facility transferring a patient should notify the receiving facility and transport personnel of 
the patient‘s colonization or infection status before transfer. 
 
 Visitors  
Visitors should perform hand hygiene before they have contact with a patient.  
 
Visitors who are not providing direct patient care should perform hand hygiene at the end of 
their visit.  No special barriers are required. 
  
Visitors who provide direct patient care must follow the guidelines for barriers and hand 
hygiene used by health care workers.  Health care facilities should provide educational 
materials to visitors. 
 
 Appropriate Antibiotic Utilization 
Staff members who prescribe antibiotics should be educated about proper antibiotic use.  
Systematic controls (such as limiting formularies) have been useful in numerous hospitals. 
 
 Education  
Staff:  Health care workers who give direct care must be educated continuously. 
 
Patients:  Develop educational materials or use reputable commercial educational tools that 
address the following issues: 
 
The reasons for isolation, the use of barriers, and the duration of practices and barriers, 
 
How to perform hand hygiene, 
 
The importance of not sharing food or beverages, 
 
The importance of maintaining a clean home environment and disinfecting common 
shared items with an approved disinfectant. 
 
Patients who are colonized with MRSA and VRE are at risk for acquiring vancomycin-resistant 
Staphylococcus aureus.  There are no national guidelines for caring for co-colonized and co-
infected patients.  However, the Iowa Antibiotic Resistant Task Force believes that clinicians 
would be wise to consult with an infectious disease specialist before treating these patients 
with vancomycin because such treatment may encourage the vancomycin-resistance gene to 
be transferred from Enterococcus species to S. aureus. 
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 Active Surveillance Cultures (ASCs) 
CDC‘s MDRO guideline acknowledges that various experts and groups interpret the literature 
on ASCs differently. Some hospitals have used ASCs successfully as part of their strategy to 
control or prevent spread of MDROs, particularly MRSA and VRE. In contrast, other hospitals 
have controlled or prevented spread of these organisms without implementing ASCs but by 
consistently applying hand hygiene and Standard Precautions. 
 
In addition, CDC notes that most studies have not included small rural hospitals or long-term-
care facilities, which are common in Iowa.  Therefore, the IARTF agrees with CDC‘s 
recommendation that health care facilities should assess their local problem by  
 defining the prevalence of specific MDROs,  
 evaluating the adherence to hand hygiene, Standard Precautions, and Contact 
Precautions, and  
 evaluating the adequacy of environmental cleaning. 
 
ASCs (on admission and periodically thereafter) may be of benefit in populations that are at 
high risk for complications from colonization or infection with MDROs and if transmission 
occurs despite optimal adherence to hand hygiene, Standard Precautions, Contact 
Precautions, and environmental cleaning. Health care facilities that elect to do ASCs should 
ensure that clinical staff, the infection prevention team, and the laboratory collaborate so that 
specimens are obtained properly and the laboratory is not overwhelmed with specimens.  
 
Readers are referred to the CDC MDRO guideline and the Institute for Healthcare 
Improvement‘s MRSA getting started kit for further discussions on this topic.   
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LONG-TERM CARE FACILITY   
 
 
The number of residents in long-term care facilities who are colonized or infected with multidrug- 
resistant organisms has increased.  The Task Force offers the following guidelines, which are 
modifications of acute care guidelines or guidelines developed by other states and facilities to assist 
in preventing and controlling resistant organisms in the long-term care setting.  This guideline 
addresses MRSA, VRE and Clostridium difficile and other multi-drug resistant organisms such as 
extended spectrum beta-lactamase (ESBL) producers or multi-drug resistant Pseudomonas in the 
long-term care facility. 
 
 
 
Long-Term Care Facility Guidelines  
for Residents with Multidrug- Resistant  
Organisms or Clostridium difficile 
 
 
 Resident Placement 
 
Admission to licensed facilities should not be denied because the resident is colonized 
or infected with an antibiotic resistant organism. 
 
Private rooms are always ideal, but in most long-term care facilities the number of private 
rooms is limited.  Routinely placing a colonized or infected resident into a private room is not 
required.  However, if possible, place residents with the same organism together in the same 
room (cohorting). 
 
When a private room is not available and cohorting residents is not possible, place the 
infected or colonized resident with another resident who is at low risk of acquisition, or of an 
adverse outcome, from infection: i.e., no immunosuppression, open wounds, or indwelling 
catheters, and not totally dependent on health care workers for activities of daily living. 
 
 Infection Prevention and Control Measures 
  
For Isolation Precautions refer to Centers for Disease Control and Prevention (CDC):  
Guideline for Isolation Precautions in Hospitals, HICPAC– 2007.  The individual resident‘s 
clinical situation is key in determining whether to implement Contact Precautions (in addition to 
Standard Precautions) for a resident infected or colonized with a multi-drug resistant organism 
(MDRO).   
  
Standard Precautions should be practiced consistently for every contact with every resident.   
 
In addition, on the basis of the site of infection or colonization and the risk of transmission to 
others, Contact Precautions may also be needed but may be modified for the long-term care 
setting. 
 (Refer to Chart for Long-Term Care Page 37) 
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Factors that affect the likelihood that a resident will shed resistant organisms should be 
considered when deciding whether to use Standard or Contact Precautions include:  
 
Resident's mental status and reliability, 
 
Presence or absence of diarrhea, 
 
Resident‘s personal hygiene, 
 
Ability to contain wound drainage with dressings, 
 
Resident‘s ability to control their urine and stool (continent or incontinent). 
 
Appropriate use of gloves and gowns should be determined on the basis of whether Standard 
or Contact Precautions are indicated.  
 
Follow Standard Precautions for all residents.  Standard Precautions include the use of 
gloves and possibly gowns for contact with uncontrolled secretions, pressure ulcers, draining 
wounds, stool incontinence, and ostomy tubes or bags.  Masks should be worn when caring 
for a resident with a cough illness.  Standard Precautions are adequate for relatively healthy 
residents (e.g., mainly independent) and for those in the following situations: 
 
Residents who are colonized with MRSA in their nares or in a superficial lesion and who 
do not have indications of infection (e.g., purulent sputum, signs of active or progressive 
wound infection). 
 
Residents who are colonized with VRE in the GI tract, but are continent of stool and 
capable of maintaining hygiene practice, e.g., hand washing. 
 
Residents with prior Clostridium difficile infection who do not have diarrhea.  The risk of 
shedding is linked to clinical signs (i.e., diarrhea).  In addition, C.difficile toxin may still 
be detectable after adequate treatment.  Therefore there is no need to obtain a 
negative test as proof of a cure. 
 
Follow Contact Precautions for other residents (e.g., those totally dependent upon health 
care personnel for health care and activities of daily living, ventilator dependent) and for those 
residents whose infected secretions or drainage cannot be contained.  Contact Precautions 
include the following:  
 
Wear a gown and gloves upon room entry when contact with the resident or      
resident‘s environment is anticipated, 
 
Gloves should be changed between procedures on the same resident if they become 
contaminated or when the health care worker moves from caring for a dirty to a clean 
site. 
 
Remove gloves gown before leaving the resident's room. 
 
Gloves are not required for casual contact outside the resident‘s room.   
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 Contact Precautions are needed in the following situations: 
 
Residents who have wounds that are colonized or infected with resistant organisms 
(MRSA or VRE) and the wounds cannot be covered fully by dressings or produce 
drainage that cannot be contained by dressings. 
 
Incontinent residents who carry resistant organisms (MRSA or VRE) in their 
genitourinary or gastrointestinal tracts and whose urine or stool cannot be contained in 
incontinence products, urine or ostomy bags. 
 
Incontinent residents with C. difficile with diarrhea or stool that is not contained in 
incontinence products. 
 
Residents with tracheostomies who have MRSA or VRE in their respiratory secretions 
and they produce significant amounts of secretions that are not contained. 
 
When a cluster of nosocomial (institutionally acquired) infections is recognized. 
 
 Hand Hygiene  
Please review pages 21-23 of this report for complete hand hygiene information. 
Hand hygiene  (i.e., hand washing or hand antisepsis) before and after resident contact and after 
removing gloves is the single most effective infection prevention and control measure for 
reducing the transmission of all organisms, including those that are antibiotic resistant. 
 
All staff that provide direct care to residents with multidrug-resistant organisms should: 
 
Perform hand hygiene with an alcohol-based product if hands are not visibly soiled or wash 
hands for at least 15 seconds if they are visibly soiled. 
 
Perform hand hygiene after every episode of resident care, 
 
Change gloves between different body sites on the same resident, 
 
Perform hand hygiene after removing gloves. 
 
Caring for patients with Bacillus anthracis, Clostridium difficile (spore formers) or 
norovirus,  
o Washing hands with non-antimicrobial or antimicrobial soap and water may 
help to physically remove spores from the surface of contaminated hands. 
o If your institution experiences an outbreak, consider using only soap and water 
for hand hygiene when caring for patients with Clostridium difficile or 
norovirus infection. ― 
 
 Residents should: 
 
Wash hands after toileting, 
 
Wash hands or use an alcohol-based hand hygiene product before leaving their room for 
common areas or before interacting with other persons. 
 
If residents are unable to wash their hands, health care workers should assist them with 
hand hygiene. 
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 Environment: 
The rooms of residents with resistant organisms can be cleaned with the facility‘s standard (EPA-
approved) disinfectant using the facility‘s standard procedures for cleaning.  The resident's room 
(particularly in those on Contact Precautions) should be cleaned daily to reduce the number of 
bacteria contaminating the environment.  
 
Specific attention should be given to bed rails, commodes, bedside tables and other surfaces that 
are frequently touched. 
   
If possible, dedicate resident care equipment to the resident. Clean and disinfect the items after 
they are no longer needed to care for the resident. If equipment must be shared, clean and 
disinfect the items between use on different residents, e.g., stethoscopes, sphygmomanometer, 
or electric thermometer.  Do not use rectal thermometers for patients with VRE. 
 
Shared bathrooms, showers, tubs 
 
Bathrooms: In situations where a resident with a resistant organism shares a bathroom with a 
non-infected or colonized roommate, the bathroom should be cleaned and disinfected using 
the facility‘s standard procedure (daily and when visibly soiled).  Commodes may be useful for 
certain residents with resistant organisms and should not be shared with roommates. 
 
Showers and tubs: Shared tubs and showers should be cleaned and disinfected per the 
facility‘s standard procedure after use by residents with resistant organisms. 
 
Teach staff which disinfectants to use and how to use them safely, removing all organic material 
before disinfecting and allowing the appropriate contact time for the disinfectant, following the 
manufacturer‘s directions. 
 
 Dishes and eating utensils: 
No special requirements are needed for dishes, glasses, cups, or eating utensils.  The 
combination of hot water and detergents used in institutional dishwashers, if used properly, is 
sufficient to decontaminate these items. 
 
 Laundry: 
Laundry staff should wear gloves and long sleeved gowns when sorting laundry. 
 
Standard Precautions are adequate for handling laundry from all residents.  However, visibly 
soiled laundry should be handled in a way that minimizes contamination of staff and the 
environment.  Special handling (i.e., double bagging, etc) is not necessary.  Laundry should not 
be rinsed at point of use. 
 
 Activities: 
Long-term care facilities are considered to be a resident's home.  Residents who have multidrug-
resistant organisms should be allowed to ambulate, socialize as usual and participate in 
therapeutic and group activities as long as body substances are contained. Barrier protection to 
contain wound drainage, feces, urine, etc. is preferred over restricting the resident. 
  
 Decolonization: 
Routine decolonization for MRSA is not recommended for residents of long-term care facilities at 
this time.  Decolonization therapy for MRSA may result in the emergence of resistance to the 
agents used and since re-colonization is common, decolonization has had little impact on the 
incidence of infections experienced by residents of long-term care facilities.  
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There is no proven decolonization regimen for VRE.  Among residents of long-term care facilities, 
VRE colonization is likely to persist for extended periods of time. 
 
Treatment of residents colonized with C. difficile is not recommended.  
 
 Criteria for Discontinuing Isolation Precautions in Residents of Long- Term Care Facilities. 
Long-term care facilities may use the criteria outlined in the acute care section on pages 27-28 to 
discontinue Contact Precautions. 
 
The likelihood of the resident transmitting resistant organisms (i.e. presence or absence of 
incontinence, diarrhea, uncontained body fluids) should be reassessed periodically. 
 
 Mechanism to Flag Residents Introduced or Reintroduced Into the Health care System 
Use a computer or other system to inform staff members about the resident‘s history of 
colonization or infection with resistant organisms at the time of admission, readmission and 
reintroduction into the health care system. This is not necessary for patients with a history of 
Clostridium difficile. 
 
 Criteria to Remove the MDRO Flag from Records of Residents 
Currently there is no set standard of removing the flag from a medical record.  Each facility 
should determine a process that works within their system and their patient population.    
 
Long-term care facilities may use the criteria outlined in the acute care section on pages        to 
remove the MDRO flag from a resident‘s record 
 
 Transferring Residents 
It is the responsibility of the facility transferring the resident to notify a receiving facility and 
transport personnel of the resident‘s colonization or infection status before transfer. 
 
 Visitors  
Visitors should perform hand hygiene before they have contact with a resident.  
 
Visitors who are not providing direct resident care should perform hand hygiene at the beginning 
and end of their visits.  No special barriers are required. 
  
Visitors who provide direct resident care must follow the guidelines for barriers and hand washing 
or hand hygiene used by health care workers. 
 
Provide educational materials to visitors. 
 
 Appropriate Antibiotic Utilization 
Prescribing staff should be educated about proper antibiotic use. Systematic controls (such as 
limiting formulary) have been useful in numerous hospitals. 
 
 Education  
Staff:  Health care workers who give direct care must be educated continuously. 
 
Residents and their visitors:  Develop educational materials or use reputable commercial 
educational tools that address the following: 
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The reasons for isolation, the use of barriers, and the duration of practices and 
barriers, 
 
Using good hand hygiene technique, 
 
Refraining from sharing food or beverages, 
 
Maintaining a clean home environment and disinfecting common shared items with 
a household disinfectant. 
  
 
Residents who are colonized with MRSA and VRE are at risk of acquiring vancomycin-resistant 
Staphylococcus aureus.  There are no national guidelines for co-colonized or co-infected residents.  
However, the Iowa Antibiotic Resistance Task Force believes that clinicians would be wise to consult 
with an infectious disease specialist before treating such residents with vancomycin.  Such treatment 
may encourage the vancomycin-resistance gene to be transferred from the Enterococcus to 
Staphylococcus aureus. 
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Long-term Care Facility:  Recommended Practices for Residents with Multidrug Resistant Organisms or Clostridium difficile 
Resident Transmission Risk Room Placement Care of Resident in Resident Room Care of Resident in Common Area Rehab Activity (RT, OT, RT) 
 
*Incontinent of stool or urine  
(VRE, C. difficile) 
 
*Diarrhea (VRE, C. difficile) 
 
*Uncontained body fluids or drainage 
(VRE or MRSA) 
 
*Cognitively impaired 
 
 
 
 
*Private room with hand hygiene and 
toilet facilities 
OR 
*Cohort with a resident with the same 
resistant organism 
OR 
*Share room with resident who does 
not have venous or arterial access 
devices , urinary catheter, trach, open 
wounds, is not on antibiotics, and is 
not immunocompromised ++ 
 
AND 
 
*Both residents are able to cooperate 
in strategies to contain their body 
secretions. 
 
 
*Wear gloves to enter room and for 
direct resident care and any contact 
with frequently touched surfaces in 
resident room. 
 
*Change gloves after contact with 
material that could contain high 
concentrations of drug resistant 
organisms, e.g., stool, and body fluids. 
 
*Remove gloves before leaving room. 
 
*Perform proper hand hygiene after 
gloves are removed. 
 
*Wear gown if substantial contact with 
resident or with environmental 
surfaces in the resident‘s room is 
anticipated. 
 
*Limit or dedicate supplies to 
resident‘s room. 
 
*Clean all equipment with disinfectant 
before removing from room.  
 
*Resident‘s clothing can be washed 
using regular detergent and dried in 
machines provided in the facility. 
 
 
(This includes dining room, hallway, 
activity room, etc.) 
 
*Case-by-case assessment when 
resident‘s body fluids, stool cannot be 
contained.   
 
*Instruct or assist resident to wash 
hands consistently and properly after 
using the toilet and before leaving 
room for common areas. 
 
*Do not allow multiple residents to 
handle  items, e.g., cards, puzzle 
pieces, and TV remote. 
 
*Gloves are not required for casual 
contact with resident outside of the 
resident‘s room.   
 
Staff wears gowns and gloves when 
cleaning spills. 
 
*If resident needs to use bathroom, 
take them back to own room; instruct 
resident about washing their hands or 
help resident wash hands t after using 
the toilet. 
 
*Surfaces contaminated by resident 
secretions or excretions should be 
cleaned and disinfected.   Have 
residents use chairs, etc that can be 
easily cleaned; avoid fabric furniture. 
+++ 
*Case-by-case assessment of resident 
leaving room when body fluids, stool cannot 
be contained. Consider doing rehab 
activities and other services in the  
resident‘s room.  Minimize sending 
residents to other sites. 
 
*Instruct resident about washing their hands 
or help the resident with wash their  hands 
after using the toilet. 
 
*Gloves are not required for casual contact 
with resident outside of the resident‘s room.  
Staff should wear gowns and gloves when 
cleaning spills. 
 
*Wipe equipment with disinfectant after 
contact with a resident and before use with 
the next resident.  
 
*Surface contaminated by residents‘ 
secretions or excretions should be cleaned 
and disinfected.  +++,  
*Continent of stool or urine (or on a 
regulated program)+ 
*No diarrhea 
*Wound drainage or body fluids is 
contained 
 
*Able to cooperate in strategies to 
contain their body secretions. 
Same as above 
 
 
*Gloves are not required for casual 
contact.  Gloves are worn for direct 
resident care and contact with 
frequently touched surfaces in 
resident‘s room. 
 
*Perform proper hand hygiene before 
entering and after leaving resident 
room. 
 
*Gowns are required only if risk of 
soiling with fecal material or infectious 
drainage is anticipated. 
*Instruct residents to wash their hands 
after using toilet and before leaving 
their room for common areas. 
 
*Instruct residents to use the toilet in 
their own rooms.  Reinforce hand 
washing. 
 
*Gloves are not required for casual 
contact with resident outside of the 
resident‘s room.  
 
Staff should wear gowns and gloves 
when cleaning spills. 
*Instruct or assist resident to wash hands 
on arrival to rehab department and before 
leaving room. 
 
*Gloves are not required for casual contact 
with resident outside of the resident‘s room.  
Staff should wear gown and gloves when 
cleaning spills. 
 
*Wipe equipment with disinfectant after 
resident contact and before next resident 
use.  
 
*Surfaces contaminated by resident 
secretions or excretions should be cleaned 
and disinfected. +++,   
+ Regulated program:  As defined by the Rehab Standards 
++ The health status of residents with drug resistant organisms and uninfected roommates should be periodically reassessed to determine whether they should continue to share a room. 
+++ Daily environmental cleaning of surfaces commonly touched by residents known to be positive for drug resistant organisms and their care givers is recommended. 
 Exception: A resident with an implanted port not being used can share a room with a resident who has drug resistant organism 
 The disinfectant must be in contact with the item to be cleaned for 10 minutes.
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Mental Health Facility 
Inpatient, Partial Hospitalization and  
Day Treatment Programs 
Guidelines for Patients and Clients 
with Multidrug Resistant Organisms or Clostridium difficile 
 
Admission Policy: Admission to a mental health facility should not be denied because the 
patient is colonized or infected with a multidrug resistant organism or has Clostridium difficile. 
 
Patients admitted to a licensed mental health facility typically do not have acute medical 
conditions, but they are at risk due to co-morbidities. Mental health facilities are somewhat 
unique in that the patients or clients are encouraged to join in group activities and may eat in a 
common dining room. These activities are important as an adjunct to their treatment regimen. 
  
It is imperative to identify those patients that are known to be colonized or infected with a 
multidrug resistant organism or Clostridium difficile based on their medical history, institution 
flagging system, or current testing results. Assessing the patient or client for active infection, 
containment of body substances and ability to comply with recommended precautions is 
necessary in developing a plan of care and providing a safe environment of care for other patient 
or clients.  
 
Isolation Precautions: For Isolation Precautions refer to Centers for Disease Control and 
Prevention (CDC) Guideline for Isolation Precautions: Preventing Transmission of Infectious 
Agents in Healthcare Settings, 2007 and Management of Multidrug- Resistant Organisms in 
Healthcare Settings, 2006.  In addition to Standard Precautions, health care workers should 
observe Contact Precautions. 
 
Standard Precautions: should be practiced consistently for every contact with patients or clients 
including hand hygiene and use of personal protective equipment such as gloves and gowns 
when contact with body substances is expected. 
 
Contact Precautions: should be utilized for patient or clients in addition to Standard Precautions 
which includes hand hygiene, use of gloves and gowns. The personal protection equipment is 
used to prevent person-to-person, person-to-environment and environment-to-person 
transmission. 
 
Infection Prevention and control Measures for Mental Health Facilities include: 
1.) Hand hygiene in mental health is usually limited to soap and water. Alcohol based hand gels are 
often limited to supervised instances. 
2.) Cleaning of the environment is per the facility‘s procedures based on health care recommended 
guidelines.  
3.) Patient or client‘s personal laundry may be their responsibility to complete as described in mental 
health policy and procedures. Laundry items such as linens and towels would be processed per 
institutional processes. 
4.) Activities are developed as appropriate to the patient or client individual and group needs. 
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5.) Decolonization would not be routinely recommended for mental health patients or clients. 
6.) Staff will be knowledgeable on how to implement Standard and Contact Precautions and how to 
use personal protective equipment and to dispose of it safely.  Education on multidrug resistant 
pathogens and Clostridium difficile and how to break the chain of transmission should be 
provided at a level of understanding for the patient or client and their visitors. If family will be 
responsible for their care on discharge they should receive information. 
7.) Transfer to long term care, acute care or another mental health setting requires that the 
presence of any multidrug resistant pathogen or Clostridium difficile be shared with the receiving 
institution.  If laboratory results are received post transfer that information is required to be 
forwarded to the receiving institution 
 
Standard Precautions with Resistant Organism colonization or Clostridium difficile in 
mental health situations as determined by: 
1. Mental health guideline chart page    for recommendations of room placement, care of patient 
or client in their room, and care of patient or client in common areas, 
2. Patients or clients who are colonized with MRSA in their nares or a superficial lesion and who 
do not have an indication of infection, 
3. Patients or clients who are colonized with VRE in the GI tract, but are continent of stool and 
capable of maintaining good hygiene practice such as hand washing, 
4. Patient or client that has prior a history of or a current Clostridium difficile infection but does 
not have diarrhea or is not incontinent of stool. The risk of shedding is linked to clinical signs 
such as diarrhea. Clostridium difficile toxin may still be detected after adequate treatment. It is 
not recommended to obtain a negative test as proof of a cure. 
 
Implementation of Contact Precautions with Resistant Organism or Clostridium difficile 
active infection and uncontained body substances in mental health situations as 
evidenced by: 
1. Refer to chart (page  ) for recommendations of room placement, care of patient or client in their 
room, and care of patient or client in common areas,  
2. MRSA or VRE in a wound with drainage that cannot contained by dressings, 
3. MRSA or VRE in sputum from a tracheostomy that cannot be contained, 
4. MRSA or VRE in stool or urine with incontinence, and not contained by incontinence products, 
5. Clostridium difficile in stool with active diarrhea that is not contained by incontinence products.   
When there is a cluster of health-care associated infections identified, Contact Precautions may 
need to be added to the care of the patients or clients with MRSA, VRE, other resistant 
organisms, or Clostridium difficile. 
Assessment of the patient or client infected with MRSA, VRE, other resistant organisms, or 
Clostridium difficile that have body substances that cannot be contained needs to be conducted 
on an individual basis. If they are unwilling, or unable, to follow recommended measures, they 
could be placing other patients or clients at risk. 
 
Partial Hospitalization or Day Treatment for patients or clients with MRSA, VRE, other 
resistant organisms, and Clostridium difficile, participation is allowed if: 
1.) Patient or clients who are colonized with MRSA in their nares or have an infection which is 
contained by dressings, 
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2.) Patients or clients who are with VRE in the GI tract but are continent of stool or able to use 
incontinent supplies and capable of maintaining hygiene. 
3.)  Patient or client with prior Clostridium difficile infections who do not have diarrhea or is capable 
of using incontinent supplies safely and maintains good hand hygiene. The risk of shedding is 
linked to clinical signs of diarrhea. Clostridium difficile toxin may still be detectable after adequate 
treatment. It is not recommended to obtain a negative test as proof of a cure. 
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MENTAL HEALTH GUIDELINES FOR PATIENTS or CLIENTS WITH RESISTANT ORGANISMS or CLOSTRIDIUM DIFFICILE 
DISEASE or RESISTANT 
ORGANISM 
ROOM PLACEMENT CARE OF PATIENT or CLIENT IN THEIR ROOM PATIENT or CLIENT IN COMMON AREAS  
(dining room, group meetings, game room, etc) 
 
Patients or clients who have had 
MRSA infection or colonization in 
the past but currently have no 
signs of active infection (no 
draining wounds or copious 
amounts of purulent sputum) 
 
Patients who have had VRE 
infection or colonization in the past 
but have no current signs of 
infection (draining wounds) and 
are continent of stool 
 
 
Patient or clients may be placed in a double 
room. If possible avoid roommates with the 
following: 
1) open skin lesions, sores or burns 
2) indwelling devices 
3) colonized or infected with a 
different resistant organism 
4)   immunosupression – AIDS,    
transplant patients, neutropenic patients or 
those on chronic steroids 
 
Use personal protective equipment (gloves, gown 
and mask) as needed per Standard Precautions. 
Masks are not needed even for patients with 
MRSA in their respiratory tract. 
 
Hand washing with soap and water immediately 
prior to leaving the room and as needed per hand 
hygiene policy. 
 
Clean equipment (BP cuffs, etc.) with appropriate 
disinfectant before removing from room. 
 
If patient is going to another area of the hospital for 
tests or procedures, notify the receiving 
department that patient is in Contact Precautions. 
 
Patient or client:  
1) May attend group meetings in any area, use dining room 
and other common areas, go to game room. 
 
2) Should be instructed to wash hands after using toilet and 
before leaving their room for common areas. 
 
3) Should be encouraged to use their room for toilet use. 
Reinforce hand washing. 
 
Staff: 
Use Standard Precautions. 
 
Common surfaces such as tables do not need to be 
disinfected after each patient contact. They should be 
cleaned on a routine basis.  
 
Patients or clients who have had 
MRSA infection or colonization in 
the past and currently have signs 
of active infection (draining 
wounds or copious amounts of 
purulent sputum) 
 
Patients or clients who have had 
VRE infection or colonization in 
the past and have current signs of 
infection (draining wounds) or are 
incontinent of stool 
 
 
Private room with hand washing and toilet 
facilities 
 
If a private room is not available, cohort 
with another patient or client known to have 
infection or colonization with the same 
organism 
 
If private room and cohort not available, 
avoid roommates with the following: 
1) open skin lesions, sores or burns 
2) indwelling devices 
3) colonized or infected with a 
different resistant organism 
4) immunosupression – AIDS,    
transplant patients, neutropenic patients or 
those on chronic steroids 
 
If drainage is uncontained, assess whether 
a private room is the only option for this 
individual. 
 
No other patient or client should be in the 
patient‘s or client‘s room. If this is 
witnessed, have them leave the room and 
wash their hands 
 
Gloves are worn for direct care and contact with 
frequently touched surfaces in the room. Masks 
are not needed even for patients or clients with 
MRSA in their respiratory tract. 
 
Hand washing with soap and water should be 
completed immediately after gloves are removed 
per hand hygiene policy. 
 
Gowns are not required except when there is a risk 
of soiling clothing with fecal material or infectious 
drainage. 
 
Clean equipment (BP cuffs, etc.) with appropriate 
disinfectant before removing from room. 
 
If patient or client is going to another area of the 
hospital for tests or procedures, notify the receiving 
department that they are in Contact Precautions 
 
Patient or client:  
1) May attend group meetings in any area, use dining room 
and other common areas, go to game room unless wound  
drainage cannot be contained.  
 
2) Should be instructed to wash hands after using toilet and 
before leaving their room for common areas. 
 
3) Should be encouraged to use their room for toilet use. 
Reinforce hand washing. 
 
4) Patient or client does not need to wear a gown, gloves or 
mask 
 
Staff: 
Use Standard Precautions 
 
Common surfaces such as tables do not need to be 
disinfected after each patient contact. They should be 
cleaned on a routine basis. 
  
Private room with hand washing and toilet 
facilities until patient is no longer having 
diarrhea 
 
No other patient or client should be in the 
patient or client‘s room. If this is witnessed, 
have them leave the room and wash their 
hands 
 
Gloves are worn for direct care and contact with 
frequently touched surfaces in the room. 
Hand washing with soap and water immediately 
after gloves are removed. 
Gowns are not required except when there is a risk 
of soiling clothing with fecal material or infectious 
drainage. 
Clean all equipment (BP cuffs, etc.) with 
appropriate disinfectant  
If patient or client is going to another area of the 
hospital for tests or procedures, notify the receiving 
department that they are in Contact Precautions 
 
Patient or client, if continent:  
  1) May attend group meetings in any area, use dining room 
and other common areas. 
  2) Should be instructed to wash hands after using toilet and 
before leaving their room for common areas. 
  3) Should be encouraged to use their room for toilet use. 
Reinforce hand washing. 
Staff: 
Use Standard Precautions 
If patient or client is not continent and stool cannot be  
contained (adult diaper), they should not be in common 
areas. 
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Guidelines for Correctional Facilities 
 
 
 
The Iowa Antibiotic Resistant Task Force endorses the Federal Bureau of Prisons   ―Management of 
Methicillin-Resistant Staphylococcus aureus - Clinical Practice Guidelines April 2011‖.  The 
guidelines can be found at:  
www.bop.gov/news/PDFs/mrsa.pdf 
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Dental 
 
 
2007 American Heart Association  
Guidelines for the Prevention of Infective Endocarditis 
 
In April of 2007 the American Heart Association (AHA) published a landmark revision in the 
guidelines for the prevention of bacterial endocarditis.  After extensive review of the worldwide body 
of scientific literature, the AHA‘s Endocarditis Committee concluded that there is not conclusive 
evidence that links invasive dental, genitourinary (GU) or gastrointestinal (GI) tract procedures with 
the development of infective endocarditis (IE).  As a result, the AHA no longer recommends routine 
antibiotic prophylaxis prior to GU or GI tract procedures and has drastically limited the scope of 
cardiac conditions that require prophylaxis. 
 
Invasive dental procedures include those which involve perforation of the oral mucosa or 
manipulation of gingival tissues or the structures surrounding the apices of teeth.  These procedures 
are known to precipitate bacteremias and include extraction of teeth, placement of implants and 
routine oral prophylaxis (cleanings).  Injection of local anesthetics, dental fillings placed above the 
gum line, and adjustment of orthodontic appliances generally do not require antibiotic prophylaxis.  
The revised guidelines reflect a paradigm change whereby the emphasis on the causation of IE has 
shifted from the infrequent bacteremias that occur during the course of dental treatment to the 
cumulative bacteremias experienced by patients in the course of daily life.  It has long been 
recognized that routine oral hygiene procedures (toothbrushing, flossing, powered irrigation) and 
mastication of food cause transient bacteremias and that the vast majority of cases of IE occur 
―spontaneously‖ and are not attributed to medical or dental procedures. 
In the previous nine reiterations of the AHA guidelines, the ―first do no harm‖ rationale prevailed, and 
it was deemed that patients with preexisting cardiac conditions known to confer only a moderate-risk 
of IE over a lifetime would benefit from antibiotic prophylaxis prior to invasive dental procedures.  
―Moderate-risk‖ conditions included a variety of non-life threatening congenital cardiac malformations, 
pathologic heart murmurs and hypertrophic cardiomyopathy. 
Currently, the AHA recommends antibiotic prophylaxis prior to invasive dental procedures only for the 
cardiac conditions which confer the highest risk of morbidity or mortality from endocarditis (Table1).  
Thus the vast majority of patients with pre-existing cardiac conditions no longer require antibiotic 
coverage. 
 
 
(Table 1) Cardiac Conditions for Which Antibiotic Prophylaxis is Necessary 
 Prosthetic cardiac valve 
 Previous infective endocarditis 
 Congenital heart disease (CHD)* 
- Unrepaired cyanotic CHD, including palliative shunts and conduits 
- Completely repaired congenital heart defect with prosthetic material or device, whether 
placed by surgery or by catheter intervention, during the first six months after the 
procedure** 
- Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch 
or prosthetic device (which inhibit endothelialization) 
 Cardiac transplantation recipients who develop cardiac valvulopathy 
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 *Except for the conditions listed above, antibiotic prophylaxis is no longer recommended for any 
other form of CHD 
**Prophylaxis is recommended because endothelialization of prosthetic material occurs within six 
months after the procedure 
 
The extensive revisions in the 2007 AHA guidelines for the prevention of infective endocarditis 
reflects the current emphasis on evidence based practice and the growing concern over the risks 
associated with the overuse of antibiotics.  These risks include development of bacterial resistance to 
antibiotics and allergic reactions to antibiotics.   
 
Antibiotic Prophylaxis for Patients with Total Joint Replacements 
 
In 2003 the American Dental Association (ADA) and the American Academy of Orthopaedic 
Surgeons (AAOS) updated their joint advisory statement regarding secondary antibiotic prophylaxis 
for patients with weight bearing prosthetic joints.   The committee concluded that prophylaxis ―should 
be considered‖ for select patients who may be at increased risk of total joint infections secondary to 
invasive dental procedures. (Table 2) 
 
(Table 2)  Patients at Potential Increased Risk of Hematogenous Total Joint Infections 
 All patients during the first two years following total joint replacement 
 Patients who are immunocompromised or immunosuppressed due to: 
- Inflammatory arthropathies (rheumatoid arthritis, systemic lupus erythematosus) 
- Drug treatment (corticosteroids, immunomodulators, etc.) 
- Radiation therapy 
 Patients with select comorbidities: 
- History of prosthetic joint infection 
- HIV infection 
- Malignancy 
- Insulin-dependent diabetes 
- Malnourishment 
 
Prior to the first joint advisory statement in 1997, all patients with prosthetic knee or hip joints were 
routinely prescribed antibiotics prior to dental treatment.  Authors have cited the morbidity, mortality 
and hospitalization costs associated with joint infections as justification for secondary prophylaxis, yet 
close examination of the literature (temporal procedure-infection associations, causative organisms 
etc.) does not support the cause and effect relationships that serve as the basis for many of these 
recommendations. 
 
Issues to Address 
 The disproportionate emphasis placed on dental bacteremias as the precipitating factor in the 
development of bacterial endocarditis and prosthetic joint infections has fostered a fear of 
litigation that continues to drive the overuse of prophylactic antibiotics in dentistry.   
 Many patients with prosthetic joints are advised to remain on secondary prophylaxis 
indefinitely despite current ADA/AAOS recommendations.  
 Outdated prophylaxis regimens that call for the initiation of oral antibiotics up to 24 hours 
before invasive procedures and maintenance for an additional two to three days continue be 
prescribed for patients with total joint replacements. 
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 Education is a key component to enhancing compliance with prophylaxis guidelines as health 
care providers, uncomfortable with the new AHA recommendations, continue to prescribe 
antibiotics inappropriately. 
 The maintenance of optimal oral hygiene together with the prompt treatment of oral infections 
to prevent metastases will prevent more cases of endocarditis and prosthetic joint infections 
than the use of prophylactic antibiotics for dental appointments. 
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HOME CARE AND HOSPICE  
 
 
Transmission risks during home care are presumed to be minimal. Since home care involves patient 
care by a limited number of personnel in settings without multiple patients or shared equipment, the 
potential reservoir of pathogens is reduced. There are no published data on indirect transmission of 
multidrug- resistant organisms (MDROs) from one home care patient to another, although this is 
theoretically possible if contaminated equipment is transported from an infected or colonized patient 
and used on another patient. 
 
 
Home Care and Hospice  
Guidelines for Patients with Multidrug Resistant Organisms 
 
 
 Barriers: 
Gloves should be used by visiting care providers when providing direct patient contact.  Family 
members and other care providers should also be instructed on appropriate use of gloves in the 
home, (e.g., when doing direct patient care and handling potentially infected secretions). 
 
As per Standard Precautions gowns should be worn if there is risk of soiling with any body fluid. 
Consider using a face shield to protect the eyes in the event of a splash or spray.  
 
Family members and other care givers should be instructed to change and wash clothing if 
clothing becomes soiled with any body fluid. 
 
 Hand Hygiene: 
Please review pages 21-23 of this report for complete hand hygiene information. 
 
Hand hygiene procedures in the home health care setting are essentially the same as in the acute 
care setting.  Health care workers should use paper towels to dry their hands after washing their 
hands and should not use the patient‘s or family member‘s towels for this purpose.  An alcohol-
based hand hygiene product may be used if the hands are not soiled (and when sinks and 
running water are not available.) 
 
Patients should have plain soap or antimicrobial soap in the home and the patient and family 
members should be instructed on appropriate hand hygiene techniques. 
Many alcohol hand gels are available over the counter.  Those containing at least 60 percent 
alcohol are useful. 
 
Care of Equipment: Care of patient equipment in the home health care setting is essentially the 
same as in the acute care setting.  Specific recommendations can be found in the APIC Guideline 
for Selection and Use of Disinfectants. 
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The home care provider should: 
Disinfect stethoscope, thermometer, and glucometer with alcohol swabs before returning to bag.  
  
Use disposable items whenever possible. 
  
 
Establish a safe working surface by placing a barrier, e.g., paper towels or newspapers between 
environmental surfaces and the care provider‘s supply bag and clean the supply bag exterior with 
a disinfectant before leaving the home. 
 
Clean reusable equipment either in the patient‘s home or bag it before leaving the patient‘s home. 
 
Patients and family caregivers should be taught the importance of: 
Changing bed linens regularly and when soiled and performing hand hygiene after completing 
such duties. 
 
Cleaning and disinfecting bathrooms and other environmental surfaces promptly that may 
become contaminated with fecal material or other secretions and excretions. 
 
Using a household disinfectant to clean surfaces in the home at least twice a week and when they 
become visibly contaminated. 
 
Environmental culturing is not necessary in the home environment. 
 
 Health care workers 
To aid in surveillance for resistant organisms health care workers should report resistant 
organisms and infections that may have been acquired during home health care to the 
appropriate person(s) in their agency. 
 
The home care or hospice agency should communicate with Infection Preventionists in other 
health care facilities that care for the same patients to ensure that infection prevention and control 
precautions are used across the spectrum of care and to aid in surveillance for resistant 
organisms. 
 
Patients in high-risk categories should be encouraged to receive influenza vaccine annually, 
unless medically contraindicated. 
 
Patients with medical indications should be encouraged to receive pneumococcal vaccine. 
 
Home health care staff may evaluate the status of other persons within the home setting when 
determining what precautions may be instituted.  
  
Necessary supplies may be left in the patient‘s home in a supply box for ready use by caregivers. 
 
Home health care staff should educate patients and families about resistant organisms.    
 
IDPH provides fact sheets online to help provide guidance regarding MRSA, VRE, Influenza, and 
Clostridium difficile. 
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www.idph.state.ia.us/adper/cade_content/epifacts/mrsa.pdf 
 
www.idph.state.ia.us/adper/cade_content/epifacts/vre.pdf 
 
www.idph.state.ia.us/adper/cade_content/epifacts/influenza.pdf 
 
www.idph.state.ia.us/idph_universalhelp/main.aspx?system=IdphEpiManual&context=Cdifficile      
_factsheet 
  
 
 Visitors 
Visitors should practice proper hand hygiene before and after visiting the patient.  Persons 
providing direct patient care should follow the guidelines for hand hygiene and use of barriers 
(gloves, gowns) as outlined above for home care nurses. 
 
Visitors with the following problems should consider deferring their visit: 
 
Recent major surgery (such as a transplant, open heart surgery), 
 
Chemotherapy. 
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OUTPATIENT HEMODIALYSIS UNITS 
 
 
Health care workers providing care to patients receiving hemodialysis in an inpatient setting should 
follow the acute care guidelines.  Precautions for patients receiving hemodialysis on an outpatient 
basis are slightly different than the precautions for acute care patients. 
 
 
Outpatient Hemodialysis Units 
Guidelines for Patients with Multidrug Resistant Organisms or  
Clostridium difficile 
 
 
Providers should follow the procedures listed on the attached chart for outpatient hemodialysis. 
 
(Refer to Chart – Page 43) 
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Hemodialysis Unit:  Recommended Practices for Patients with VRE or MRSA or C. difficile 
 
 
Patient Transmission Risk Patient Placement and 
Precautions 
Care of Patient Dialyzer Use Environmental Other 
 
 
*Incontinent of stool or urine 
(VRE) 
 
*Diarrhea (VRE or  
C. difficile) 
 
*Uncontained body fluids or 
drainage (VRE or MRSA) 
 
 
*A private room with a hand 
washing sink, dispenser for 
alcohol-based hand hygiene 
products and toilet is ideal. 
WITH 
*Contact precautions 
OR 
*Cohort patients with the 
same resistant organisms in 
one area of the dialysis unit, 
in so far as practical. 
 
*When practical, cohort 
staff. 
 
*Instruct patient to wash 
hands or help patient wash 
their hands after using the 
toilet or touching body fluids 
or drainage. 
 
*Proper hand hygiene is 
essential for all staff. 
 
*An adequate number of 
staff is important so that 
those who care for 
patients with VRE or 
MRSA do not need to 
respond to emergencies 
with other patients. 
 
 
*Gowns are not required; 
gowns are needed if 
health care worker‘s 
clothing could become 
soiled with fecal material 
or infectious drainage. 
 
*Health care workers 
should wear gowns when 
they clean spills of body 
fluids or drainage. 
 
Dialyzer reuse is 
acceptable 
 
*Cultures of other patients, unit 
staff, or environmental surfaces 
are not routinely indicated.   
 
*Standard guidelines for 
disinfection of dialysis machines, 
chairs, and environmental 
surfaces after each patient use 
should be followed meticulously. 
 
*Equipment should not be shared 
between patients colonized or 
infected with MRSA or VRE and 
patients who are NOT colonized 
or infected with those organisms.   
 
Equipment must be cleaned and 
disinfected before use by another 
patient. 
 
*Notify Infection Prevention 
staff when patient with VRE 
or MRSA is identified. 
 
*Is continent of stool or urine 
(VRE) 
*No diarrhea (VRE) 
*Wound drainage or body 
fluids is contained (VRE or 
MRSA) 
 
Contact precautions, except 
a private room is not 
required. 
 
*Instruct patient or assist 
patient with washing hands 
after using the toilet. 
 
Same as above 
 
Emphasis on hand 
hygiene. 
 
Same as above 
 
Same as above 
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SCHOOLS AND CHILD CARE 
 
 
There are no national guidelines for addressing the issue of antibiotic-resistant bacteria in the school 
and child care settings; however, occasionally transmission of antibiotic resistant bacteria has been 
documented in these situations.  For example, MRSA has been transmitted among high school 
wrestlers, likely due to direct skin-to-skin contact and skin abrasions.  In most cases, transmission 
requires direct contact with contaminated material, including the following: 
 MRSA:  Skin or respiratory secretions or material from an infected site. 
 VRE:  Stool, urine, or material from an infected site. 
Persons whose hands are contaminated with these organisms can transmit them to another person. 
 
In most schools and child care centers, children do not have specific risk factors for acquiring 
resistant organisms or of having serious infections, should transmission occur.  Furthermore, 
colonization would probably not persist for long periods of time in these populations.  Unrecognized 
colonization probably occurs, but does not appear to pose a serious threat to the children.  However, 
good hygienic practices are important at all times.  The Task Force offers the following guidelines for 
workers in the school and child care setting. 
 
 
Guidelines for Schools and Child Care 
Guidelines for Persons with Multidrug Resistant Organisms 
 
 
 Good hygienic practices are important at all times.  Drug resistant organisms are spread: 
  By unwashed hands, 
 By environmental contamination with feces or other body fluids. 
 
 The following preventive measures should be promoted to staff, parents, and children. 
Practice good hand washing procedures outlined below. 
 
    Do not use antibiotics for viral upper respiratory tract infections (colds). 
 
    Use antibiotics only as prescribed. 
 
    Do not take someone else's medication. 
 
    Do not share your medication with others. 
 
    Do not take old or outdated medication. 
 
Use caution in formulating policies that specify the criteria children must meet before returning to 
child care or to school.  Policies that require ill children to be treated with antibiotics regardless of 
necessity before they can return to the facility will encourage unnecessary use of antibiotics and 
promote development of resistance. 
 
Clean and cover all open wounds before allowing staff and children to return to regular activities 
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Do not permit sick employees to have physical contact with children or handle food. 
 
 Hand washing 
Hand washing is the simplest, most effective way to prevent infection. 
 Keep fingernails short and do not wear artificial nails. 
 Instruct children and staff to wash their hands for 15 seconds with warm, running, and 
soapy water. 
 Instruct children to sing the song ―Happy Birthday” twice or the ―ABC’s” song to themselves 
while washing hands.  When they are done singing the song, they can stop washing their 
hands. 
 Instruct children to rub hands together including all surfaces of fingers, palms and backs of 
hands. 
 Thoroughly rinse and dry hands. 
 Use paper towels to turn off faucet. 
 Always use disposable towels in child care or food preparation settings. 
 Do not use a common hand towel.   
 Do not use a single damp cloth to wash a group of children‘s hands. 
 Do not use a standing basin of water to rinse hands. 
 Use liquid or foam soap. If bar soap is used, use soap racks to ensure drainage and use 
small bars. 
 Children should wash their hands  
Upon arrival, 
Before handling or eating food,  
After using the bathroom or being diapered, 
After playing outside or on the playground,  
After sneezing and touching one‘s nose, 
       After handling pets and animals, and 
Before going home.   
 Staff should always wash their hands  
Upon arrival, 
Before preparing food and bottles,  
Before giving medications, 
      Before eating,  
      After using the rest room, 
      After assisting children with toileting or diapering,  
      Before and after giving first aid, and 
      Before going home.  
 
 Children learn by example.  Let them observe good hand washing technique from the 
adults who care for them. 
 
 Supervise children while they wash their hands to ensure they use proper technique. 
 
 If hand washing facilities are not available because of special activities, such as field visits, 
use alcohol based gels (for children over 24 months of age). 
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 Gloves 
Staff should wear gloves when cleaning spills of bodily fluids (urine and blood), and administering 
first aid if there is contact with any wound (cut, sore or scrape) that has material that could be 
transmitted to another surface. 
 
 Environment 
Use disposable cleaning cloths.  If reusable cloths are used, they must be laundered on a regular 
basis with chlorine bleach in the wash water.  The use of sponges is not recommended.  
Remember that germs thrive on moist surfaces. 
 
Surfaces contaminated by a child's bodily fluids should be cleaned and disinfected with a 
household disinfectant.  Use chairs and other furniture that can be easily cleaned; avoid fabric 
furniture. 
 
 Laundry 
Clothing, linens, and towels that are heavily soiled with body fluids should be washed by 
themselves in detergent and bleach using the hottest cycle possible for that fabric. 
 
If the child care center does not launder clothes, put soiled clothes in a sealed waterproof bag to 
be sent home.  Tell parents how to launder the items properly. 
 
Articles that are not soiled with bodily fluids can be washed with other clothing. 
 
 Waste Management 
Place all disposable wastes like dressings and bandages into plastic bags.  Tie the bags securely 
and discard them with the regular trash. 
 
 Eating 
Staff members who prepare food must wash their hands thoroughly before touching the food or 
equipment. 
 
Consider using prepackaged snacks. 
 
Do not allow children to share dishes and utensils, take bites of another child's food or touch other 
children‘s food. 
 
Make sure children wash their hands before eating. 
 
A dishwasher is the preferred method for washing, rinsing, and disinfecting dishes and eating 
utensils. 
 
If the facility does not have a dishwasher, wash the dishes with dish soap and hot water and 
disinfect with chlorinated (bleach) water for at least 1 minute.  (1 1/2 T. liquid bleach for each 
gallon of water) (This recommendation is for ALL dishes and utensils used by all staff and 
students.) 
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 Preventing Transmission 
 
Students COLONIZED with antibiotic resistant organisms should not be excluded from 
school or child care. 
 
Students with an infection due to antibiotic resistant bacteria should be under appropriate 
medical care before being allowed to return. 
 
In situations when infected students (or colonized students who are unable to control secretions) 
need to participate in school or child care, the school should follow clinical guidelines for 
preventing transmission.  These precautions may designate specific space for the child‘s use or 
exclude the child from activities where direct contact with other children may occur (e.g., 
wrestling).   
 
Education about the risks and transmission of antibiotic resistant organisms should be available to 
staff of schools and child care facilities. 
 
Any student with a draining skin lesion could transmit potentially infectious agents to others. 
When a student with a suspected or confirmed skin infection is in the classroom, infection 
prevention and control measures (based on Centers for Disease Control and Prevention [CDC] 
guidance) should include, but may not be limited to:  
 
 Keeping the wound covered. All skin infections, particularly those that produce pus must 
be covered with a clean, dry bandage to contain the drainage.  
 
 Providing wound care or dressing changes following Contact Precautions. Contaminated 
dressings and other materials associated with the infected lesion should be placed in a 
plastic bag before discarding as appropriate.  
 
 Practicing good basic hygiene. The infected student, medical staff, sport team, staff and 
anyone expected to have contact with the infected student must be diligent with hand 
hygiene.  
 
 Prohibiting students from sharing personal items. Instruct students and athletes to avoid 
sharing personal hygiene supplies and other items such as athletic clothing, towels, 
uniforms, skin balms, skin lubricants, razors, and certain sports equipment at all times.  
 
 Laundering soiled clothing appropriately. Parents and caregivers should be instructed to 
wash clothes and other soiled items (e.g. towels, sheets) with hot water and laundry 
detergent as appropriate. They should also be advised to dry items in a hot dryer to help 
eliminate bacteria when possible.  
 
 Cleaning environmental surfaces. Establish a written procedure and schedule for routine 
surface cleaning of shared athletic equipment and toys. Clean and disinfect environmental 
surfaces, athletic equipment and toys that has been in contact with potentially infectious 
wound drainage, blood, or non-intact skin utilizing an EPA-registered disinfectant cleaner 
that meets the requirements of the Bloodborne Pathogens Standard developed by the 
Occupational Safety and Health Administration.  
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VETERINARY MEDICINE 
 
 
Antibiotics are important therapeutic agents used in the practice of veterinary medicine for the 
treatment and control of diseases in animals.  The use of these agents is necessary for the animals‘ 
welfare and for the maintenance of an abundant, wholesome and safe food supply.  Appropriate use 
of antibiotic agents in the veterinary setting will minimize the emergence of resistant organisms in 
animals and will ensure the efficacy of antibiotics in humans and animals in the future. 
 
 
Guidelines for Veterinary Medicine 
 
 
The Iowa Veterinary Medical Association recommends that when veterinarians use antibiotics in the 
practice of veterinary medicine, judicious use principles should be implemented as outlined in the 
American Veterinary Medical Association (AVMA) Judicious Therapeutic Use of Antimicrobial 
Guidelines.   
 
This position statement is copied below and also can be found at: 
www.avma.org/issues/policy/jtua.asp 
 
American Veterinary Medical Association Judicious Therapeutic Use of Antimicrobials 
(Oversight:FSAC; Approved by the AVMA Executive Board, November 1998; revised April 2004, 
November 2008) 
 
 Position Statement 
When the decision is reached to use antimicrobials for therapy, veterinarians should strive to 
optimize therapeutic efficacy and minimize resistance to antimicrobials to protect public and 
animal health. 
 
 Objectives  
Support development of a scientific knowledge base that provides the basis for judicious 
therapeutic antimicrobial use.  
Support educational efforts that promote judicious therapeutic antimicrobial use.  
 Preserve therapeutic efficacy of antimicrobials.  
Ensure current and future availability of veterinary antimicrobials.  
 
 Strategies  
 Facilitate development and distribution of appropriate antimicrobial use guidelines by practitioner 
species-interest groups.  
 Improve scientifically based therapeutic practices through education. 
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 Recognized Needs  
 Improved monitoring and feedback systems for antimicrobial use and resistance patterns.  
 
  Research to improve scientifically based therapeutic practices.  
 
 Judicious Use Principles  
 Preventive strategies, such as appropriate husbandry and hygiene, routine health monitoring, and 
immunization, should be emphasized.  
 Other therapeutic options should be considered prior to antimicrobial therapy.  
 Judicious use of antimicrobials, when under the direction of a veterinarian, should meet all 
requirements of a veterinarian-client-patient relationship.  
Prescription, Veterinary Feed Directive, and extralabel use of antimicrobials must meet all the 
requirements of a veterinarian-client-patient relationship.  
Extralabel antimicrobial therapy must be prescribed only in accordance with the Animal Medicinal 
Drug Use Clarification Act amendments to the Food, Drug, and Cosmetic Act and its regulations.  
Veterinarians should work with those responsible for the care of animals to use antimicrobials 
judiciously regardless of the distribution system through which the antimicrobial was obtained.  
 Regimens for therapeutic antimicrobial use should be optimized using current pharmacological 
information and principles.  
Antimicrobials considered important in treating refractory infections in human or veterinary 
medicine should be used in animals only after careful review and reasonable justification.  
Consider using other antimicrobials for initial therapy.
1
 
Use narrow spectrum antimicrobials whenever appropriate.  
     Utilize culture and susceptibility results to aid in the selection of antimicrobials when clinically 
relevant. 
 Therapeutic antimicrobial use should be confined to appropriate clinical indications.  Inappropriate 
uses such as for uncomplicated viral infections should be avoided.  
Therapeutic exposure to antimicrobials should be minimized by treating only for as long as 
needed for the desired clinical response.  
 Limit therapeutic antimicrobial treatment to ill or at risk animals, treating the fewest animals 
indicated.  
Minimize environmental contamination with antimicrobials whenever possible.  
Accurate records of treatment and outcome should be used to evaluate therapeutic regimens.  
1
 In this context, this principle takes into account development of resistance or cross-resistance to 
important antimicrobials.  
 
 Glossary 
(Incorporated into general glossary of report.) 
 
 Veterinarian/Client/Patient Relationship (VCPR) -- A VCPR exists when all of the following 
conditions have been met:  
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The veterinarian has assumed the responsibility for making clinical judgments regarding the 
health of the animal(s) and the need for medical treatment, and the client has agreed to follow the 
veterinarian's instructions.  
The veterinarian has sufficient knowledge of the animal(s) to initiate at least a general or 
preliminary diagnosis of the medical condition of the animal(s). This means that the veterinarian 
has recently seen and is personally acquainted with the keeping and care of the animal(s) by 
virtue of an examination of the animal(s) or by medically appropriate and timely visits to the 
premises where the animal(s) are kept.  
The veterinarian is readily available for follow-up evaluation, or has arranged for emergency 
coverage, in the event of adverse reactions or failure of the treatment regimen. 
Veterinary Feed Directive (VFD) Drug--The VFD category of medicated feeds was created by 
the Animal Drug Availability Act of 1996 to provide an alternative to prescription status for certain 
therapeutic animal pharmaceuticals for use in feed.  Any animal feed bearing or containing a VFD 
drug shall be fed to animals only by or upon a lawful VFD issued by a licensed veterinarian in the 
course of the veterinarian's professional practice. 
(EB 11/98; EB approved SCAR revision 4/04 oversight:SCAR)   
 
Additional position statements and guidelines for use of antimicrobials for various species of 
animals for specific diseases are also provided on this website.  
 
 
On June 28, 2010, the U.S. Department of Health and Human Services, Food and Drug 
Administration, Center for Veterinary Medicine issued draft guidance on the Judicious Use of 
Medically Important Antimicrobials in Food-Producing Animals. This draft guidance is currently 
being distributed for comment purposes only. The draft guidance can be accessed at: 
www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustr
y/UCM216936.pdf. 
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PREVENTION AND CONTROL MEASURES  
IN THE COMMUNITY 
 
 
Approximately 75 years ago, people began to rely on antibiotics to treat previously deadly infections.  
Unfortunately, once antibiotic use began, organisms also began to develop resistance.  While most 
antibiotics are still very effective, some pathogenic bacteria have developed resistance, in part 
because antibiotics have been misused to treat viral infections and other conditions that do not 
respond to antibiotics.  If these practices are not changed, all presently available antibiotics may 
become useless.  Antibiotics are, without a doubt, incredible tools for fighting bacterial infections; 
however, because of this, many people have come to believe that antibiotics can cure anything.  This 
mode of thought can result in misuse of antibiotic agents: 1) antibiotics can be mistakenly prescribed 
to treat viral infections and 2) patients may stop treatment when they feel better and save the rest of 
the antibiotic pills for future illnesses.  When antibiotics are misused, resistant bacteria can develop.  
 
Many people in the community mistakenly believe that all bacteria are bad and should be killed to 
protect human beings.  This belief has led industry to develop, advertise, and sell innumerable 
household cleaning products with ―antimicrobial‖ compounds to supposedly ―protect‖ us from all the 
bad bacteria around us.  In reality, most of the bacteria around, and in us are not only not bad, but 
are actually necessary to keep us healthy.  The indiscriminant use of these cleaning compounds in 
the community is not necessary, or desirable, and may allow antibiotic resistant bacteria to develop.  
See section on Methacillin-Resistant Staphylococcus aureus (MRSA) for a discussion of MRSA in the 
community, decolonization, prevention, diagnosis and treatment of these infections. 
 
Communities can prevent and control antibiotic resistant organisms through coordinated efforts.  For 
example, health care organizations in a tri-state region around Sioux City, Iowa significantly reduced 
the colonization rate of vancomycin-resistant Enterococcus (VRE) of inpatients and long-term care 
residents.  A community-wide task force developed in  
1997 coordinated a prevention and control effort including all 32 health care facilities in the area.  
Over a year and a half, the documented colonization rate of VRE was decreased by almost half.  
 
Clearly, the philosophy and practices regarding bacteria and antibiotic use must change.  The Iowa 
Antibiotic Resistant Task Force has developed simple recommendations to educate the public on 
how to stop the development and spread of antibiotic resistant bacteria in the home and community.  
These recommendations emphasize preventing infections and the more judicious use of antibiotics 
and antimicrobial products and may allow the prevention and treatment of illness while ensuring that 
antibiotics work in the future. 
 
Actions to protect yourself, your family, and your community against antibiotic resistance: 
 
 
Wash your hands. Proper hand washing is the easiest, most effective way to prevent diseases from 
spreading and to prevent the need to use antibiotics. 
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 When to wash your hands  
After using the bathroom, 
After changing diapers,   
After handling pets,  
Before handling food,  
After handling blood or other bodily fluids. 
 How to wash your hands 
Use regular soap and warm, running water.   
Scrub hands and fingernails for at least 15 seconds.  Sing the song ―Happy Birthday‖ 
twice or the ―ABCs‖ song to help time 15 seconds. 
Scrub all parts of the hands including fingers, palms, and the back of hands. 
Dry your hands with a clean or disposable towel.  
Store bar soap on a soap rack to keep it dry. 
Consider using alcohol-based hand wipes or gels only when water is not available and 
hands are not visibly dirty.  If hands are visibly dirty, then the dirt must be removed by 
washing before gels can be effective. 
 Keep home, work, and play areas smoke-free. Smoking and second-hand smoke make 
children and everyone else in the home more susceptible to respiratory diseases.  Decreasing 
respiratory diseases will decrease the use of antibiotics. 
 Warm, soapy water or a mild bleach solution (1 teaspoon liquid bleach to 1 quart water) 
is almost always the best way to clean your home.  Limit the use of ―antibacterial‖ or 
―antimicrobial‖ products when cleaning your house.  Remember, antibacterial or antimicrobial 
products kill both good and bad bacteria, and are almost never needed.  With fewer good 
bacteria present, bad bacteria may have more opportunities to grow and develop antibiotic 
resistance.  
 Use antimicrobial products only when 
Regular soap and water are not available,  
Someone in the household has a weakened immune system,   
Someone in the household is ill with a contagious disease, for example someone in the 
home has diarrhea. 
 Store and handle food properly. It is important to store and handle food properly because 
bad bacteria can come into your house on the foods you buy.  When handling food: 
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Wash your hands before and after preparing food.   
Wash all raw fruits and vegetables. 
Use a separate cutting board for raw meat to prevent bacteria from the raw meat 
touching other food. 
Properly cook all meats, especially ground meat and poultry.   
Clean all kitchen surfaces with disposable towels, warm soapy water, or a mild bleach 
solution (1 teaspoon liquid bleach to 1 quart water) after preparing food.  
Regularly wash dishcloths and towels.  
If sponges are used, run them through the dishwasher or washer and dryer on a 
frequent, regular basis. 
 Ensure your family’s vaccinations are current. Vaccines greatly reduce the risk of infection 
from certain diseases; thus, fewer antibiotics are needed. 
 Don’t automatically ask for antibiotics from your doctor.  Antibiotics kill both good and bad 
bacteria but they do not kill viruses.  Viruses are responsible for most common illnesses such 
as colds, sore throats and influenza.  Taking antibiotics for an illness caused by a virus will not 
make you feel better and can cause bacteria to become resistant to the antibiotic.  
Furthermore, taking antibiotics may cause other problems such as diarrhea or yeast infections.   
Let your doctor decide when antibiotics are appropriate. 
 If your doctor prescribes antibiotics, finish all of the antibiotics even if you start to feel 
better.  Taking the entire prescription will kill all of the bacteria so they can‘t develop antibiotic 
resistance.  If you feel the need to stop treatment early, ask your doctor first. 
 Never share your prescription with someone else, and never save antibiotics for future 
use.  If you take the wrong antibiotic or one that has expired, some bacteria can survive and 
can develop resistance to antibiotics. 
 Do not flush expired or unused antibiotics down the toilet or pour down the sink.  
Unused antibiotics thrown out this way can end up in the streams, and possibly in our water 
supply, which can allow bacteria to develop resistance.  Put all unused or expired antibiotics 
into a plastic bag, tie the bag shut, and place in the garbage.  Consider taking them to local 
hazardous waste disposal site or to your pharmacist for disposal.  
 Wash your hands often when you are ill.  Washing your hands when you are ill will prevent 
others from catching your illness.  If fewer people are ill, the need for antibiotics will decrease 
and so will the risk of acquiring resistant bacteria. 
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Methicillin-Resistant Staphylococcus aureus  
 
 
In the U.S., Staphylococcus aureus is the most common cause of skin and soft-tissue infections and 
is also a common cause of invasive infections acquired in hospitals. Despite the growing prevalence 
of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals, these strains had been 
uncommon in the community. Thus, MRSA infections were considered to be primarily acquired in the 
health care setting and were referred to as health care acquired (HA-MRSA). Treatment and control 
of MRSA were focused in health care facilities. In the late 1990s, clinicians began identifying patients 
who acquired MRSA infections in the community and who did not have the usual health care-
associated risk factors. Most of these infections were skin and soft tissue infections (SSTI) but some 
were serious invasive infections, including necrotizing pneumonia following influenza or influenza-like 
illness. Patients with SSTI often had recurrent infections. Recently, investigators have reported that 
USA300 isolates, the most common community-associated MRSA (CA-MRSA) strain, are causing 
nosocomial or health care-associated infections.  
 
Various investigators have used different definitions of CA-MRSA. Epidemiologically oriented studies 
often use a definition based on when the positive cultures were obtained relative to hospital 
admission (i.e., before admission or within the first 24-72 hours of hospitalization). Some studies also 
exclude patients with established risk factors for MRSA such as recent hospitalization, hemodialysis, 
indwelling catheters, etc. Other studies define CA-MRSA based on the MRSA strain causing the 
infection. See below for a discussion of CA-MRSA strains. 
 
The incidence of CA-MRSA varies by age and several studies have found that persons infected by 
CA-MRSA strain are younger than patients infected with HA-MRSA. CA-MRSA strains have caused 
outbreaks in several discrete populations, including children (particularly those in childcare centers), 
high school, college, and professional athletes (e.g., fencing, rugby, football, soccer, and wrestling), 
soldiers, prisoners, homeless persons, intravenous drug users, and men who have sex with men. 
Certain ethnic groups also have been associated with outbreaks including Pacific Islanders, Native 
Americans/Alaska Natives, and Pacific and Canadian aboriginals.  
 
The CA-MRSA strain identified in the U.S. was called MW2 and later identified to be in the USA400 
pulsetype. Subsequently, pulsetype USA300 has become the most common CA-MRSA strain in most 
areas of the U.S. where the molecular epidemiology of CA-MRSA has been studied. In Iowa, 
USA300 now causes about 15 percent of the MRSA invasive infections reported to the State 
Hygienic Laboratory (SHL). CA-MRSA isolates have been identified in many countries but the 
pulsetypes often are different than those identified in the U.S. However, essentially all CA-MRSA 
strains carry the genes for methicillin-resistance on the genetic element SCCmec type IV and 
produce Panton-Valentine leukocidin (PVL), which is lethal to neutrophils. To date, investigators have 
not determined whether PVL is an important virulence factor.  
 
In general, CA-MRSA isolates are susceptible to multiple other antibiotic agents. However, Han et al. 
and Diep, et al. recently identified CA-MRSA isolates from San Francisco and from Boston that were 
multiply resistant. Diep et al. found that CA-MRSA isolates from an outpatient clinic in Boston were 
resistant to erythromycin (96%), levofloxacin (85%), clindamycin (57%), and tetracycline (30%). 
Moreover 18 isolates (18%) were resistant to all four of these agents and 12 of these isolates (67%) 
were also high-level mupirocin resistant. These isolates were primarily among USA300-0247 subtype 
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and they carried the resistance determinants on a plasmid. Thus, these isolates can transmit the 
resistance determinants to other isolates. To date, these isolates have not been identified among 
invasive CA-MRSA from Iowa.  
 
Nasal colonization with CA-MRSA, like other strains of MRSA, is a risk factor for subsequent infection 
with the colonizing strain. However, investigators have not determined how often nasal carriage 
precedes infection and how often nasal carriage is important in transmission of CA-MRSA during 
outbreaks. A recent study by Ellis et al. found that intranasal mupirocin did not prevent infections 
among soldiers who were colonized with CA-MRSA and did not prevent non-carriers from becoming 
colonized. At present, we do not know whether decolonizing the nares prevents infections in 
individual patients or prevents transmission during outbreaks. More studies are needed before 
routine decolonization is recommended. Readers interested in more information on decolonization 
are referred to the chapter by Herwaldt and Boyce in the references listed at the end of this 
document. 
 
Johnson et al. found environmental contamination in an outpatient setting in which several health 
care workers became colonized with USA300. These investigators suggested that the environment 
might help transmit these strains in the hospital. 
 
Many MRSA have inducible clindamycin resistance. The typical susceptibility test will identify these 
isolates as susceptible to this agent but these isolates will express resistance to oxacillin or 
dicloxacillin if the patient is treated with this agent. Thus, clinicians should ask their microbiologist 
whether the laboratory conducted a D-test before treating any patient whose isolate is reported to be 
erythromycin resistant and clindamycin susceptible. If the isolate is D-test negative, the patient may 
be treated with oxacillin or dicloxacillin. If the isolate is D-test positive, the patient should be treated 
with another agent. 
 
The Infectious Diseases Society of America (IDSA) published guidelines for the diagnosis and 
treatment of SSTI in 2005 (an update projected for Fall, 2011) and CDC developed guidelines for 
management of MRSA in the community. Both IDSA and CDC indicate that furuncles (―boils‖) and 
carbuncles often can be treated without antimicrobial agents unless the lesion is surrounded by 
extensive cellulitis or the patient has fever. Many of these infections will respond to moist heat or to 
incision and drainage. Patients with more serious abscesses, extensive cellulitis, or necrotizing 
fasciitis and patients who have infections such as osteomyelitis, bloodstream infections, or 
endocarditis must be treated with systemic antibiotic agents. Milder infections often can be treated 
with oral trimethoprim-sulfamethoxazole, tetracyclines, or clindamycin (D-test negative) but more 
serious infections, in general, should be treated with intravenous vancomycin.  
Many physicians routinely treat skin and soft tissue infections (SSTIs) such as furuncles, abscesses, 
or cellulitis empirically with β-lactam antibiotics. As noted in the previous paragraph IDSA and CDC 
indicate that many of these infections can be treated successfully without antibiotic agents. Given 
that incidence of CA-MRSA has increased to the point that they cause over 90 percent of SSTI in 
many areas, β-lactam antibiotics should not be the preferred agents for patients whose infections 
need both local treatment and antibiotic therapy. 
 
Prevention 
Education of health care providers, patients, caregivers, high-risk populations, and appropriate 
organizations about CA-MRSA and adherence to basic infection prevention and control principles is 
key preventive strategy. CDC recommends the following preventive measures for patients with skin 
and soft tissue infections and their close contacts: 
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1. Keep wounds that are draining covered with clean, dry, bandages. 
2. Clean hands regularly with soap and water or alcohol-based hand gel (if hands are not visibly 
soiled). Always clean hands immediately after touching infected skin or any item that has come in 
direct contact with a draining wound. 
3. Maintain good general hygiene with regular bathing. 
4. Do not share items that may become contaminated with wound drainage, such as towels, clothing, 
bedding, bar soap, razors, and athletic equipment that touches the skin. 
5. Launder clothing that has come in contact with wound drainage after each use and dry thoroughly. 
6. If you are not able to keep your wound covered with a clean, dry bandage at all times, do not 
participate in activities where you have skin to skin contact with other persons (such as athletic 
activities) until your wound is healed. 
7. Clean equipment and other environmental surfaces with which the bare skin of multiple persons 
has contact. Use an over the counter detergent and disinfectant that specifies S. aureus on the 
product label and is suitable for the type of surface being cleaned. 
 
CDC has also developed information for athletes and athletic programs that are similar to their 
general recommendations in that they emphasize maintaining good hygiene and a clean 
environment. In addition, CDC recommends that infected athletes should be excluded from 
participating in sports if their wounds cannot be properly covered during participation. CDC defines 
"properly covered" as: 
 
―. . . the skin infection is covered by a securely attached bandage or dressing that will 
contain all drainage and will remain intact throughout the activity.‖  
 
Moreover, athletes should perform hand hygiene before and after changing bandages and should 
place used bandages in the trash. Athletes with active infections or open wounds should not use 
common-use water facilities (e.g., swimming pools or whirlpools and therapy pools that are not 
cleaned between athletes) until their infections and wounds are healed.  
 
As noted previously, investigators have not determined conclusively whether decolonization prevents 
recurrent infections, particularly in the community setting. Clinicians have used numerous regimens in 
their attempts to prevent recurrences, including various combinations of topical (e.g., mupirocin) and 
systemic (e.g., trimethoprim-sulfamethoxazole, tetracyclines, clindamycin, linezolid) antibiotic agents 
and antiseptic body washes (chlorhexidine, hexachlorophene, triclosan, and dilute bleach baths). 
Decolonization regimens have been associated with antibiotic resistance among MRSA isolates, 
even among isolates obtained from patients who were not treated with the agent to which the isolates 
are resistant. Thus, clinicians should use these regimens prudently.  
 
Zoonotic considerations with MRSA 
MRSA has caused infections in companion animals including dogs, horses and less frequently, in 
cats. Animals can become colonized from humans then transmit to other animals or to humans. 
 
If patients continue to have recurrent infections despite decolonization attempts and environmental 
cleaning, clinicians could obtain cultures from family members and try decolonizing those who are 
colonized. If patients continue to have infections, clinicians could ask the patients whether they have 
cats, dogs or horses and suggest that they have their veterinarian screen the animals for MRSA 
carriage.  
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Emerging zoonotic issues related to a new strain of MRSA 
Investigators in Europe and Canada have identified a novel MRSA, known as clonal complex (CC) 
398 based on multilocus strain typing (Armand-Lefeyre et al). In the Netherlands, isolates of this type 
have been obtained from food animals – swine, poultry and beef (veal). Transmission appears to be 
from direct animal contact, not through ingestion of food (e.g., as a foodborne zoonosis). MRSA 
CC398 consists of 8 MLST types, the predominant type being sequence type (ST)398 and a range of 
closely related protein A (spa) gene types (i.e., t011, t034, t108, and t1793). 
 
Voss et al. reported a prevalence of MRSA, primarily CC398, in Dutch pig farmers that was greater 
than 760 times higher than among other patients admitted to Dutch hospitals. Molecular typing 
demonstrated that MRSA was transmitted from pigs to pig farmers, among pig farmers and their 
family members, and from a patient to a nurse. A subsequent study found that 4.6 percent of 
veterinarians and veterinary students were colonized with MRSA compared with the usual rate of one 
percent among the general population. 
 
In the U.S., investigators are studying both the sources of MRSA in animals and the prevalence of 
MRSA in animal populations and the humans associated with them. A recent survey of a large swine 
operation in Iowa and Illinois identified CC398 in the nares of swine and their handlers. Additional 
studies are ongoing to provide further information about the sources, transmission and diversity of 
MRSA strains present among animals in the U.S. To date, MRSA CC398 has not been identified 
among the invasive MRSA isolates submitted to SHL from Iowa residents.  
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Clostridium difficile                 
 
 
 
 
Clostridium difficile (C. difficile) is a spore-forming Gram-positive anaerobic bacillus that is the most 
commonly identified causative agent of antibiotic-associated diarrhea and pseudomembranous 
colitis. This pathogen has caused numerous outbreaks of  
health care-associated diarrhea that were extremely difficult to control. C. difficile is usually not 
multidrug-resistant but some strains have become resistant to clindamycin and some to 
fluoroquinolones. Exposure to antibiotic agents is the primary risk factor for C. difficile associated 
diarrhea (CDAD)
 
and the antibiotics most frequently associated with increased risk of C. difficile 
infection include third generation cephalosporins, clindamycin, vancomycin, and fluoroquinolones. 
 
This organism can be transmitted within the health care setting by mechanisms similar to those 
transmitting MRSA, VRE, and other resistant organisms. C. difficile may be transmitted from patient 
to patient on the hands of health care workers and from the contaminated environment. C. difficile 
may cause greater morbidity in elderly persons and may be a marker for increased risk of mortality, 
particularly for residents of long-term-care facilities.  
 
Epidemic Strain 
Investigators recently identified a new C. difficile strain that has caused numerous large outbreaks of 
severe CDAD. The mortality, relapse, and complication rates related to this strain are higher than 
those for other C. difficile strains. This increased virulence is presumably associated with higher 
levels of toxin production by fluoroquinolone-resistant strains belonging to PCR ribotype 027, pulsed-
field gel electrophoresis (PFGE) type NAP1, REA (restriction endonuclease analysis) type BI and 
toxinotype III. This strain carries the genes for binary toxin and has an 18-bp deletion and a 
frameshift mutation in tcdC that are thought to deregulate the production of toxins A and B. These 
strains produce 16-times more toxin A and 23-times more toxin B in vitro than toxinotype 0 strains. 
Despite being susceptible to metronidazole, the epidemic strain may not respond as well to this agent 
as do other strains, possibly because it is very virulent. Thus, clinicians must monitor patients 
carefully to be sure they are responding to therapy and that their condition does not deteriorate. 
Drudy, et al. recently identified a mutation in gyrA that is associated with fluoroquinolone resistance 
in the epidemic C. difficile strain PCR-027. These investigators suggest that health care facilities may 
need to restrict use of all fluoroquinolones to prevent or control outbreaks caused by the epidemic 
strain rather than the usual practice of changing from one quinolone to another because several of 
these agents have been independently associated with CDAD. 
Prevention 
The primary prevention strategy is maintaining robust gastrointestinal normal flora by limiting use of 
antibiotic agents. Physicians should prescribe antibiotic agents only when they are needed and they 
should stop treatment as soon as possible. In addition, physicians should target the specific infecting 
agent with antibiotic agents that have the narrowest possible spectrum. Moreover, health care 
workers must practice good hand hygiene and clean the environment adequately. Agents used in 
antiseptic hand washes or rubs and EPA-registered environmental disinfectants do not reliably kill C. 
difficile spores. Thus, CDC‘s hand hygiene guideline suggests that ―Washing hands with non-
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antimicrobial or antimicrobial soap and water may help to physically remove spores from the surface 
of contaminated hands‖ and their FAQ sheet suggests that health care facilities that are experiencing 
an outbreak of CDAD use only soap and water for hand hygiene. Moreover, the CDC environmental 
guideline states that hypochlorite-based products should be used to disinfect environmental surfaces 
in patient-care areas where surveillance and epidemiology indicate ongoing transmission of C. 
difficile. Category II.‖  
The CDC recommends that health care facilities monitor the number of CDAD cases and, especially 
if rates increase, the severity of disease and patient outcomes. If the infection prevention team finds 
that the rate of CDAD or the severity of CDAD cases has increased, they should reassess 
compliance with the recommended infection prevention measures including: hand hygiene, Contact 
Precautions, and environmental cleaning and disinfection. If compliance with infection prevention 
practices is optimal, CDC recommends that health care facilities review antibiotic use to determine 
whether particular antimicrobials are associated with cases CDAD.  
 
C. difficile in Iowa 
Investigators have not determined the incidence of CDAD in Iowa. The epidemiology of CDAD in two 
small hospitals has been described. In one hospital, a serious outbreak of CDAD occurred during a 
severe influenza season. Data from chart reviews suggested that half of the patients who received 
treatment for bacterial pneumonia before they developed C. difficile infection may not have had 
pneumonia. Excessive use of the hospital's new pneumonia care plan during the influenza season 
may have contributed to the intensity of this outbreak. In the other hospital, CDAD was not 
associated with exposure to antibiotic classes that are typically associated with CDAD, but was 
instead related to the total number of antibiotics used to treat patients. Case patients had a larger 
cumulative number of days of antibiotic use (P =.004) and they received a larger total number of 
antibiotic agents during hospitalization (P =.001) than did the control patients. Antibiotic use ratios 
were about 40 percent higher for both case and control patients at the smaller hospital compared 
with the antibiotic use ratio at the University of Iowa Hospitals and Clinics, a large academic medical 
center. In addition, a survey of Iowa‘s long-term-care facilities (LTCF) revealed that C. difficile is 
present in Iowa LTCFs, but many C. difficile infections probably remain undiagnosed because the 
facilities do not have protocols for identifying patients who have CDAD. According to CDC‘s posted 
map, the NAP1 strain of C. difficile has been reported in Iowa. 
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Resistant Gram-negative Organisms 
                         
 
 
Multidrug-resistant Gram-negative organisms have become major pathogens in many health care 
settings. Fortunately, they have not become common pathogens in Iowa. However, given the ease of 
travel, frequent over use of antibiotic agents, and use of antibiotic agents in agriculture, these 
organisms could become more frequent. Multidrug-resistant Gram-negative organisms can cause 
significant morbidity and mortality and early initiation of appropriate antibiotic therapy reduces 
morbidity and mortality. Because initial therapy is almost always empiric, physicians must know which 
multi-resistant Gram-negative pathogens are common in their facility or geographic area, which of 
these organisms are likely to cause infections in their patient population, and the usual antibiotic 
susceptibility patterns for the most common Gram-negative pathogens. For example, common 
resistant Gram-negatives include those that are resistant to fluoroquinolones, those that produce 
extended spectrum beta-lactamases [(ESBLs); e.g., E. coli and Klebsiella spp.], and those that 
produce Bush Gp. 1 (Amp C) cephalosporinases (e.g., Serratia spp., Enterobacter spp., Citrobacter 
spp.). Moreover, multidrug-resistant non-fermenting organisms, such as Pseudomonas aeruginosa, 
Acinetobacter spp.,and Stenotrophomonas maltophilia are becoming important pathogens in many 
intensive care units in the U.S., particularly those where carbapenems (imipenem/meropenem) are 
used extensively. In fact, rates of the most important resistances - fluoroquinolone resistance, ESBL 
production, and multiply (i.e., pan) resistant organisms - continue to increase and development of 
new antibiotic agents is not keeping pace. 
Gram-negative organisms often carry their resistance determinants on plasmids or transposons that 
can move from one bacteria to another, including moving from one species to another species. 
Consequently, these organisms can cause explosive outbreaks, some of which involve more than 
one species.  
Risk factors for infection or colonization with resistant Gram-negative organisms include: 
• Age,  
• Duration of hospitalization, 
• Intensive care unit admission, 
• Renal insufficiency, 
• Immunosuppression (including neutropenia, hematologic malignancy, and transplantation) 
• Prior operations, 
• Antibiotic use (including the number of antibiotic agents, duration of treatment, and the specific 
types of antibiotics (e.g., cephalosporins), 
• Device use (including central venous catheters, urinary catheters, endotracheal tubes),  
• Exposure to a source (including infected or colonized patients, contaminated inanimate 
objects, and health care workers who do not practice good hand hygiene. 
 
 
In general, infection prevention precautions are the same for resistant Gram-negative organisms as 
for MRSA and VRE. However, less has been written about precautions for Gram-negative organisms 
compared with the resistant Gram-positive organisms. In non-outbreak settings, patients with 
multidrug-resistant Gram-negative organisms should be placed in Contact Precautions. If these 
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patients are readmitted they should remain in Contact Precautions if they have an active infection 
with a multidrug-resistant Gram-negative organism or if surveillance cultures of the previous site(s) of 
infection or colonization remain positive. If all of these cultures are negative, contact precautions 
could be lifted.    
 
Implementing Contact Precautions, cleaning the environment well, screening patients for specific 
resistant Gram-negative organisms (usually with cultures of the perirectal area or stool and cultures 
of tracheal aspirates or sputum for organisms causing respiratory infections) and controlling use of 
specific antibiotic agents or classes of antibiotic agents have all been useful for controlling spread of 
these organisms in specific settings. Moreover, investigators stopped some outbreaks by identifying 
contaminated reservoirs or faulty practices. Patients who are no longer exposed to antibiotic agents 
may be able to clear the resistant Gram-negative organisms or the organisms may become 
undetectable by our current diagnostic tests. However, patients with these organisms usually cannot 
be decolonized by treatment with other antibiotic agents.   
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Glossary 
                                                                     
 
 
Airborne Precautions:  Precautions that apply to patients known or suspected to be infected with 
epidemiologically important pathogens that can be transmitted widely by air currents and may 
become inhaled by or deposited on a susceptible host within the same room or, depending on 
environmental factors, over a longer distance from the source patient.  These precautions are 
designed to reduce the risk of such airborne transmission of infectious agents through personal 
protection devices, such as N95 masks, and special air handling and ventilation systems, such as 
airborne infection isolation rooms.  (Adapted from CDC HICPAC guidelines). 
 
Alcohol-Based Hand Rub:  An alcohol-containing preparation designed to reduce the number of 
viable microorganisms on the hands.  Such preparations contain 60 – 90 percent ethanol or 
isopropanol alcohol.   
 
Antibiotic:  (as used in IARTF Report) A chemical substance that has the capacity to inhibit the 
growth or to kill bacteria. 
 
Narrow Spectrum Antibiotic:  An antibiotic effective against a limited number of   
bacterial genera often applied to an antibiotic active against either Gram-positive or 
Gram-negative bacteria but not both.  
Broad Spectrum Antibiotic:  An antibiotic effective against a large number of bacterial 
genera; generally describes antibiotics effective against both Gram-positive and Gram-
negative bacteria.  
 
Antibiotic Resistance:  A property of bacteria to inactivate or exclude antibiotics or a mechanism 
that blocks the inhibitory or killing effects of antibiotics. 
 
Antimicrobial:  (as used in IARTF Report) An agent that kills microorganisms or suppresses their 
multiplication or growth.  
 
Antimicrobial Soap:  Soap (i.e., detergent) containing an antiseptic agent. 
 
Antiseptic Agent:  Antimicrobial substances (e.g. alcohols) that are applied to the skin to reduce the 
number of microorganisms. 
 
Asymptomatic:  Without objective evidence of disease or condition. 
 
Cohort:  Any defined group of persons selected for a special purpose or study.  (From the Latin 
cohors, warriors, the tenth part of a legion). 
 
Cohorting:  Method to isolate separate infectious persons from susceptible ones.  To group persons 
with the same infection together. Cohorting of staff is to assign specific staff to a group of patients 
and not have them do care on the unaffected persons. 
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Colonization:  Propagation of a microorganism on or within a host without causing cellular injury or 
infection.  A colonized host can serve as a source of infection.  Carriers are often said to be colonized 
with a pathogen. 
 
Contact Precautions:  Precautions that apply to patients known or suspected to be infected or 
colonized with epidemiologically important microorganisms that can be transmitted by direct or 
indirect contact.  Direct-contact transmission involves skin-to-skin contact and physical transfer of 
microorganisms to a susceptible host from an infected or colonized person, while indirect-contact 
transmission involves contact of a susceptible host with a contaminated intermediate object.  
(Adapted from CDC HICPAC guidelines). 
Culture:  The growth of microorganisms on or in substances (especially laboratory media prepared 
for this purpose). 
 
Decolonization:  Administration of topical and or systemic antimicrobial agents for the purpose of 
eradicating carriage of particular bacteria by an individual. 
 
Droplet Precautions:  Precautions that apply to any patient known or suspected to be infected with 
epidemiologically important pathogens that can be transmitted by infectious droplets generated from 
the source person during coughing, sneezing, or talking or during the performance of certain 
procedures such as suctioning or bronchoscopy.  Unlike airborne precautions, because droplets 
travel only short distances (three to six feet) and do not remain suspended in the air, special air 
handling and ventilation are not required to prevent droplet transmission.  (Adapted from CDC 
HICPAC guidelines). 
 
Hand Antisepsis:  Refers to either washing hands with an antimicrobial soap or to rubbing an 
alcohol-based waterless product on the hands until they are dry.   
 
Hand Hygiene:  General term that applies to either hand washing with plain soap or hand antisepsis 
by washing with an antiseptic soap or by using an alcohol-based hand rub. 
 
Hand washing: Cleaning hands with plain, (i.e., non-antimicrobial) soap, water and friction. 
 
Health Care Provider:  A person who is trained and licensed to give health care. Also, a place 
licensed to give health care. Doctors, nurses, hospitals, skilled nursing facilities, some assisted living 
facilities, and certain kinds of home health agencies are examples of health care providers. (From the 
Medicare web site). 
Immunocompromising:  Ability to attenuate the immune response by administration of 
immunosuppressive drugs, by irradiation, by malnutrition, or by some disease processes (e.g., 
cancer). 
 
Infection:  The entry and multiplication of an infectious agent in body tissues of man or animal, 
resulting in cellular injury. 
 
Infection Prevention and Control Precautions:  Measures used for decreasing the risk of 
transmission of microorganisms, particularly in health care facilities or when otherwise providing 
medical care.  These fall into standard, contact, droplet, and airborne categories, which are also 
defined in this section. (Adapted from CDC HICPAC guidelines). 
 
Isolation:  The separation, for the period of communicability, of infected persons or animals from 
those that are not infected, in such places and under such conditions as will prevent the direct or 
indirect transmission of the infectious agent from those infected to those who may be susceptible or 
who may spread the agent to others. 
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Morbidity:  Any departure from a state of well-being. 
 
Nosocomial:  A term used to denote a disease or condition acquired within a health care setting, for 
example a hospital-acquired infection. 
Pathogen:  An agent capable of causing disease. 
 
Prophylaxis:  Measures taken to prevent the development or spread of disease. 
 
Resistance:  The sum total of host mechanisms which interpose barriers to invasion or multiplication 
of infectious agents, or that prevent damage by the agent's toxic products.  
Standard Precautions:  Precautions designed for the care of all patients in health care facilities 
regardless of their diagnosis or presumed infection status and intended to reduce the risk of 
transmission of microorganisms from both recognized and unrecognized sources of infection.  The 
main focus is on hand hygiene, the use of protective barriers, and the proper handling of clinical 
waste.  The precautions apply to (1) blood; (2) all body fluids, secretions, and excretions (except 
sweat), regardless of whether or not they contain visible blood; (3) non-intact skin; and, (4) mucous 
membranes.  (Adapted from CDC HICPAC guidelines.) 
Surveillance of Disease:  The continuing scrutiny of the aspects of the occurrence and spread of a 
disease that are pertinent to effective prevention and control. 
 
Susceptible:  A person or animal lacking sufficient resistance to a particular pathogenic agent to 
prevent disease if exposed. 
 
Transmission Mode:  The means by which disease organisms are spread. For the purposes of this 
plan, the term applies to how they are spread to humans. 
Vaccine:  A preparation containing killed or living whole microorganisms or a fraction of the 
organisms having antigenic properties.  Vaccine is employed to induce, in the recipient, a specific 
active immunity to an infectious agent (usually an antibody response). 
 
Virus:  Minute organisms not visible with ordinary light microscopy.  They can reproduce only inside 
of a host cell.  
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